ClinicalTrials.gg
CompletedNCT03970733Updated Apr 21, 2023Results posted

Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis

A Phase 2 interventional study of VLA15 and Placebo in Lyme Borreliosis, sponsored by Pfizer. Completed at 5 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-21.

Sponsored by Pfizer · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
246
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Lyme Disease with a site in United States — 15 open to participants now, 17 under way, 2 of them phase 3. Lyme Disease · United States.

Enrollment
9th of 33
246 · median 72
Started
2019
with 5 others
Phase 2
6 of 54
none open now
Registered
26th of 54
by date
Lead sponsor
8 of 54
Pfizer

Among the 54 studies in Lyme Disease with a site in United States, this one is the 9th largest by enrollment of the 33 interventional ones that give a count, is one of 6 that started in 2019, is one of 6 in phase 2, and was the 26th registered.

Lyme Disease

98 studies on the registry are indexed under Lyme Disease; 27 are open to participants now.

Browse Lyme Disease studies →

Open to participants now

15 of the 54 studies in Lyme Disease with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Lyme Disease studies recruiting now, 11 (61%) set no upper age limit and 3 (17%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Lyme Disease with a site in United States, or all of them as a file.
02

Study summary

In the Main Study Phase a total of 246 subjects were randomized 2:2:1 into three treatment groups to receive either VLA15 with Alum (lower or higher dose) or Placebo. Main Study Phase vaccinations were administered as intramuscular injections on Day 1, Day 57 and Day 180.

In the Booster Phase subjects from the higher dose group who completed their primary immunization schedule according to protocol will be randomized 2:1 to receive an additional higher dose VLA15 vaccination or Placebo at Month 18.

Study duration in the Main Study Phase per subject is a maximum of 20 months. Overall study Duration is estimated to be 22 months.

Study duration per subject in the Booster Phase is a maximum of approximately 13 months.

Study duration per subject in the Main Study Phase and Booster Phase together is estimated to be a maximum of approximately 33 months.

Overall study duration (i.e., First-Subject-In to Last-Subject Out/ end of Booster Phase) is estimated to be approximately 37 months.

Read the detailed description

This is a randomized, observer-blind (subject, Sponsor and investigator/site staff involved in Clinical Evaluation of subjects are blinded), Placebo controlled, multicenter Phase 2 study.

In Main Study Phase a total of 246 healthy subjects,aged 18 to 65 years, were randomized 2:2:1 to receive either VLA15 with Alum (lower or higher doser Placebo. Main Study Phase vaccinations were administered as intramuscular injections on Day 1 (Month 0), Day 57 (Month 2) and Day 180 (Month 6).

Subjects from the higher dose group who completed their primary immunization schedule according to protocol, will be randomized 2:1 to receive an additional injection of the higher dose VLA15 with Alum or Placebo in a Booster Phase. The additional vaccination is administered as intramuscular injection approximately 18 months after the first immunization.

03

Conditions studied

  • Lyme Borreliosis

Browse trials for

Keywords

  • VLA15
  • Lyme Borreliosis
  • Vaccine
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria - Main Study Phase:

  • Subject is aged 18 to 65 years at the day of screening
  • Subject is of good general health, including subjects with pharmacologically controlled chronic conditions;
  • Subject has an understanding of the study and its procedures, agrees to its provisions,and gives written prior to any study-related procedures;
  • If subject is of :
  • Subject has a negative serum pregnancy test at screening;
  • Subject agrees to employ adequate measures for the duration of the study.

Inclusion Criteria - Booster Phase:

  1. Randomization into higher dose group in the Main Study Phase
  2. No relevant protocol deviation in the Main Study Phase, i.e., included in the Per-Protocol population for the Day 208 interim analysis of the Main Study;
  3. Subject is of good general health, including subjects with pharmacologically controlled chronic conditions;
  4. Subject has an understanding of the study and its procedures, agrees to its provisions, and gives written informed consent prior to any study-related procedures;
  5. If subject is of childbearing potential:

    1. Subject has a negative Urine pregnancy test before booster vaccination;
    2. Subject agrees to employ adequate birth control measures for the duration of the study

Exclusion Criteria - Main Study Phase:

  • Subject has a chronic illness related to Lyme borreliosis (LB), an active symptomatic LB as suspected or diagnosed by a physician, or received treatment for LB within the last 3 months prior to screening;
  • Subject received previous vaccination against LB.;
  • Subject had a tick bite within 4 weeks prior to vaccination visit;
  • Subject has a medical history of or currently has a disease (e.g. cardiovascular, respiratory, neurologic, psychiatric conditions) which poses a risk for participation in the study, based on investigators judgement, such as individuals with poorly controlled or unstable disease, ongoing suspected or active inflammation, or poor compliance with pharmacologic treatment. Subjects with pharmacologically controlled conditions like osteoarthritis, depression, or asthma are eligible;
  • Subject has a medical history of or currently has a neuroinflammatory or disease, including Guillain Barré Syndrome;
  • Subject has a known thrombocytopenia, bleeding disorder, or received anticoagulants in the three weeks prior to each study vaccination, contraindicating I.M. vaccination as judged by the investigator;
  • Subject has received an active or passive immunization within 28 days before or after any vaccination; except for influenza (seasonal or pandemic) vaccines which may be administered outside a 7-days interval before or after any trial vaccination;
  • Subject has received any other non-registered medicinal product in another clinical Trial within 28 days prior to VLA15 vaccination and throughout the entire study period or has received a registered medicinal product in another clinical Trial within 28 days prior to VLA15 vaccination and up to Day 208;
  • Subject has a known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired immunodeficiency, including infection with (HIV), Status post organ transplantation or immuno-suppressive therapy within 30 days prior to first vaccination. Immuno-suppressive therapy is defined as administration of chronic (longer than 14 days) prednisone or equivalent >=0.05 mg/kg/day. Topical and inhaled are allowed;
  • Subject has a history of anaphylaxis or severe allergic reactions or a known or allergic reactions to one of the components of the vaccine; Subject had any in the past 5 years. If treatment for cancer was successfully completed more than 5 years ago and the malignancy is considered to be cured, the subject may be enrolled;
  • Subject had acute febrile infections within 10 days prior to first vaccination;
  • Subject is pregnant (positive serum pregnancy test at screening), has plans to become pregnant during the course of the study or is lactating at the time of enrollment. Women of childbearing potential that are unwilling or unable to employ an adequate birth Control measure for the duration of the study.
  • Subject has donated blood or blood-derived products (e.g. plasma) within 30 days or received blood or blood-derived products (e.g. plasma) within 90 days prior to first vaccination in this study or plans to donate or use blood or blood products during the course of the study;
  • Subject has any condition that, in the opinion of the investigator, may compromise the subject's well-being, might interfere with evaluation of study endpoints, or would Limit the subject's ability to complete the study;
  • Subject is committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities);
  • Subject is in a dependent relationship with the sponsor, an investigator or other study team member, or the study center. Dependent relationships include close relatives and household members (i.e. children, partner/spouse, siblings, parents) as well as employees of the investigator or study center personnel.

Exclusion Criteria - Booster Phase:

  1. Subject met an individual stopping criterion during the Main Study Phase;
  2. Subject has developed a chronic illness related to Lyme borreliosis (LB), an active symptomatic LB as suspected or diagnosed by a physician, or received treatment for LB within the last 3 months prior to vaccination visit;
  3. Subject has developed a clinically relevant disease (e.g. cardiovascular, respiratory, neurologic, psychiatric conditions) which poses a risk for further participation in the study, based on investigators judgement, such as individuals with poorly controlled or unstable disease, ongoing suspected or active inflammation, or poor compliance with pharmacologic treatment;
  4. Subject has developed a neuroinflammatory or autoimmune disease, including Guillain Barré Syndrome;
  5. Subject has developed an immunodeficiency, including known infection with human immunodeficiency virus (HIV), status post organ transplantation, or immuno-suppressive therapy within 30 days prior to vaccination visit. Immuno-suppressive therapy is defined as administration of chronic (longer than 14 days) prednisone or equivalent >= 0.05 mg/kg/day. Topical and inhaled steroids are allowed;
  6. Subject has developed anaphylaxis or severe allergic reactions;
  7. Subject has developed allergic reactions to one of the components of the vaccine;
  8. Subject has developed a malignancy;
  9. Subject has developed thrombocytopenia or received anticoagulants in the 3 weeks prior to the booster vaccination contraindicating I.M. vaccination as judged by the investigator;
  10. Subject has received any other non-registered medicinal product in another clinical trial within 28 days prior to VLA15 booster vaccination at Month 18 or plans to participate in another clinical trial with a non-registered medicinal product until Month 24;
  11. Subject is pregnant, or plans to become pregnant prior to Month 24, or is lactating. Women of childbearing potential that are unwilling or unable to employ an adequate birth control measure for the duration of the study;
  12. Subject has developed any condition that, in the opinion of the investigator, may compromise the subject's well-being, might interfere with evaluation of study endpoints, or would limit the subject's ability to complete the study;
  13. Subject has been committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities);
  14. Subject is in a dependent relationship with the sponsor, an investigator or other study team member, or the study center. Dependent relationships include close relatives and household members (i.e. children, partner/spouse, sibling).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
246 participants (actual)

Study arms

  • Experimental
    VLA15 with Alum lower dose

    Main Study Phase: VLA15 with Alum lower dose - Booster Phase: arm discontinued

    Biological: VLA15

  • Experimental
    VLA15 with Alum higher dose

    Main Study Phase: VLA15 with Alum higher dose - Booster Phase: VLA15 higher dose or placebo

    Biological: VLA15

  • Placebo comparator
    Placebo

    Main Study Phase: placebo - Booster Phase: arm discontinued

    Biological: Placebo

Interventions

  • BiologicalVLA15

    a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate

  • BiologicalPlacebo

    PBS (Phosphate Buffered Saline)

06

What researchers measure

Primary outcomes

  1. GMTs for IgG Against Each OspA Serotype

    Geometric Mean Titers (GMTs) for Immunoglobulin G (IgG) against each Outer Surface Protein A (OspA) serotype ST1 to ST6, determined by Enzyme-Linked Immunosorbent Assay (ELISA) at Day 208 (Month 7)

    Time frame: Day 208 (Month 7)

Secondary outcomes

  1. GMTs for IgG Against Each OspA Serotype During the Main Study Phase

    GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 365 (Month 12) and 545 (Month 18).

    Time frame: At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 365 (Month 12) and Day 545 (Month 18)

  2. SCRs for Each OspA Serotype Specific IgG During the Main Study Phase

    Seroconversion Rate (SCR) for each Outer Surface Protein A (OspA) serotype specific IgG ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18). Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): greater than or equal to (\>=) 4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants. Percentages are based on the number of participants with non-missing observations.

    Time frame: Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)

  3. GMFR as Compared to Baseline for IgG Against Each OspA Serotype During the Main Study Phase

    Geometric Mean Fold Rise (GMFR) as compared to baseline for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18).

    Time frame: Day 1 (baseline from where comparison was done), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)

  4. GMTs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 18 - 49 Years

    GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 18 - 49 years.

    Time frame: At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)

  5. GMTs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 50 - 65 Years

    GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 50 - 65 years.

    Time frame: At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)

  6. SCR for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 18 - 49 Years

    SCR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 18 - 49 years. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): \>=4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants.

    Time frame: Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)

  7. SCR for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 50 - 65 Years

    SCR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 50 - 65 years. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): \>=4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants.

    Time frame: Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)

  8. GMFRs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 18 - 49 Years

    GMFR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 18 - 49 years.

    Time frame: Day 1 (baseline), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)

  9. GMFRs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 50 - 65 Years

    GMFR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 50 - 65 years.

    Time frame: Day 1 (baseline), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)

  10. Percentage of Participants With Serious Adverse Events (SAEs) During the Main Study Phase

    SAE was any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. Two-sided 95% confidence intervals were calculated according to Altman method.

    Time frame: From Day 1 of vaccination up to Day 545 (Month 18)

  11. Percentage of Participants With Related SAEs During the Main Study Phase

    SAE was any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.

    Time frame: From Day 1 of vaccination up to Day 545 (Month 18)

  12. Percentage of Participants Adverse Event of Special Interest (AESIs) During the Main Study Phase

    AESIs were defined as serious or non-serious AEs which were of scientific and medical concern specific to the investigational product. Two-sided 95% confidence intervals were calculated according to Altman method.

    Time frame: From Day 1 of vaccination up to Day 545 (Month 18)

  13. Percentage of Participants With Related AESIs During the Main Study Phase

    AESIs were defined as serious or non-serious AEs which were of scientific and medical concern specific to the investigational product. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.

    Time frame: From Day 1 of vaccination up to Day 545 (Month 18)

  14. Percentage of Participants With Unsolicited AEs During the Main Study Phase

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant temporally associated with the use of investigational product, whether or not related to investigational product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up (more than 6 days after vaccination) for solicited symptoms. Two-sided 95% confidence intervals were calculated according to Altman method.

    Time frame: From Day 1 of vaccination up to Day 545 (Month 18)

  15. Percentage of Participants With Related Unsolicited AEs During the Main Study Phase

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant temporally associated with the use of investigational product, whether or not related to investigational product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up (more than 6 days after vaccination) for solicited symptoms. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.

    Time frame: From Day 1 of vaccination up to Day 545 (Month 18)

  16. Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Each and After Any Vaccination During the Main Study Phase

    Solicited local AEs included pain, tenderness, induration (hardening), swelling and erythema (redness). Solicited systemic AEs included headache, myalgia (muscle pain), arthralgia (joint pain), fever (oral body temperature), flu-like symptoms, nausea, vomiting and fatigue. Two-sided 95% confidence intervals were calculated according to Altman method.

    Time frame: Up to 7 days after Vaccination 1, 2 and 3; Up to 7 days after any vaccination

  17. Percentage of Participants With SAEs, AESIs, Solicited and Unsolicited AEs Stratified by Age Group During the Main Study Phase

    Percentage of participants with SAEs, AESIs, solicited and unsolicited AEs during main study phase stratified by age group 18-49 years and 50-65 years were reported. SAE: any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. AESI: any AEs of scientific/medical concern specific to study vaccine. Solicited AE: predefined reactions at injection site or systemic reactions after each vaccination. Unsolicited AE: any untoward medical occurrence in participant associated with use of study vaccine, whether or not related to study vaccine, reported in addition to solicited and any solicited symptom with onset outside specified period of follow-up. Two-sided 95% confidence intervals were calculated according to Altman method.

    Time frame: From Day 1 of vaccination up to Day 545 (Month 18)

  18. GMTs for IgG Against Each OspA Serotype (ST1 to ST6): Booster Per-protocol (PP) Population

    GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24, and Month 30. The outcome measure was planned to be analyzed for Booster PP population from Day 1 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.

    Time frame: At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30

  19. SCRs for Each OspA Serotype Specific IgG (ST1 to ST6): Booster PP Population

    SCR for each OspA serotype specific IgG ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24, and Month 30. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): greater than or equal to (\>=) 4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants. Percentages are based on the number of participants with non-missing observations. The outcome measure was planned to be analyzed for Booster PP population from Day 29 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.

    Time frame: Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30

  20. GMFR as Compared to Baseline for IgG Against Each OspA Serotype (ST1 to ST6): Booster PP Population

    GMFR as compared to baseline for IgG against each Osp serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24 and Month 30 were reported in this outcome measure. The outcome measure was planned to be analyzed for Booster PP population from Day 1 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.

    Time frame: Day 1 (baseline from where comparison was done), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30

  21. GMFR as Compared to Day 208 for IgG Against Each OspA Serotype (ST1 to ST6): Booster PP Population

    GMFR as compared to Day 208 for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Month 19, Month 24 and Month 30. The outcome measure was planned to be analyzed for Booster PP population from Day 208 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.

    Time frame: Day 208 (from where comparison was done), Month 19, Month 24 and Month 30

  22. GMFR as Compared to Month 18 (Pre-booster) for IgG Against Each OspA Serotype (ST1 to ST6): Booster PP Population

    GMFR as compared to Month 18 (pre-booster) for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Month 19, Month 24 and Month 30. The outcome measure was planned to be analyzed for Booster PP population.

    Time frame: Month 18 (from where comparison was done), Month 19, Month 24 and Month 30

  23. GMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 18 - 49 Years

    GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24 and Month 30 stratified by age group: 18 - 49 years. The outcome measure was planned to be analyzed for Booster PP population from Day 1 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.

    Time frame: At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30

  24. GMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 50 - 65 Years

    GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24 and Month 30 stratified by age group: 50 - 65 years. The outcome measure was planned to be analyzed for Booster PP population from Day 1 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.

    Time frame: At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30

  25. SCR for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 18 - 49 Years

    SCR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24 and Month 30 stratified by age group: 18 - 49 years was presented in this outcome measure. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): \>=4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants. The outcome measure was planned to be analyzed for Booster PP population from Day 29 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.

    Time frame: Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30

  26. SCR for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 50 - 65 Years

    SCR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24, and Month 30 stratified by age group: 50 - 65 years. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): \>=4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants. The outcome measure was planned to be analyzed for Booster PP population from Day 29 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.

    Time frame: Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30

  27. Percentage of Participants With SAEs During the Entire Booster Phase

    SAE was any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. Two-sided 95% confidence intervals were calculated according to Altman method.

    Time frame: From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months)

  28. Percentage of Participants With Related SAEs During the Entire Booster Phase

    SAE was any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.

    Time frame: From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months)

  29. Percentage of Participants With Adverse Event of Special Interest (AESIs) During the Entire Booster Phase

    AESIs were defined as serious or non-serious AEs which were of scientific and medical concern specific to the investigational product. Two-sided 95% confidence intervals were calculated according to Altman method.

    Time frame: From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months)

  30. Percentage of Participants With Related AESIs During the Entire Booster Phase

    AESIs were defined as serious or non-serious AEs which were of scientific and medical concern specific to the investigational product. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.

    Time frame: From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months)

  31. Percentage of Participants With Unsolicited AEs During the Booster Phase up to Month 19

    An unsolicited AE includes any untoward medical occurrence in a clinical investigation participant temporally associated with the use of investigational product, whether or not related to investigational product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up (more than 6 days after vaccination) for solicited symptoms. Two-sided 95% confidence intervals were calculated according to Altman method.

    Time frame: From Day of vaccination in booster phase (Month 18) up to Month 19 (Approximately for 1 Month)

  32. Percentage of Participants With Related Unsolicited AEs During the Booster Phase up to Month 19

    An unsolicited AE included any untoward medical occurrence in a clinical investigation participant temporally associated with the use of investigational product, whether or not related to investigational product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up (more than 6 days after vaccination) for solicited symptoms. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.

    Time frame: From Day of vaccination in booster phase (Month 18) up to Month 19 (Approximately for 1 Month)

  33. Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Booster Vaccination

    Solicited local AEs included pain, tenderness, induration (hardening), swelling and erythema (redness). Solicited systemic AEs included headache, myalgia (muscle pain), arthralgia (joint pain), fever (oral body temperature), flu-like symptoms, nausea, vomiting and fatigue. Two-sided 95% confidence intervals were calculated according to Altman method.

    Time frame: Within 7 days after booster vaccination

  34. Percentage of Participants With SAEs, AESIs, Solicited and Unsolicited AEs Stratified by Age Group During the Booster Phase

    Percentage of participants with SAEs, AESIs, solicited and unsolicited AEs during booster phase stratified by age group 18-49 years and 50-65 years were reported. SAE: any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. AESI: any AEs of scientific/medical concern specific to study vaccine; Solicited AE: predefined reactions at injection site or systemic reactions after each vaccination. Unsolicited AE: any untoward medical occurrence in participant associated with use of study vaccine, whether or not related to study vaccine, reported in addition to solicited and any solicited symptom with onset outside specified period of follow-up.

    Time frame: SAEs and AESIs: From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months); AEs: From Day of vaccination in booster phase (Month 18) up to Month 19 (Approximately for 1 Month)

07

Results

Posted Jul 8, 2021

Participant flow

Main Study Phase (18 Months)
Participant flow — Main Study Phase (18 Months)
MilestoneVLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlaceboBooster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
Started97985100
Completed89844600
Not completed814500
Withdrew: Withdrawal by subject07200
Withdrew: Moved from study area21000
Withdrew: Lost to follow-up55300
Withdrew: Other11000
Booster Phase (Approx. 12 Months)
Participant flow — Booster Phase (Approx. 12 Months)
MilestoneVLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlaceboBooster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
Started0003919
Completed0003918
Not completed00001
Withdrew: Lost to follow-up00001

Outcome measures

PrimaryGMTs for IgG Against Each OspA Serotype

Geometric Mean Titers (GMTs) for Immunoglobulin G (IgG) against each Outer Surface Protein A (OspA) serotype ST1 to ST6, determined by Enzyme-Linked Immunosorbent Assay (ELISA) at Day 208 (Month 7)

Time frame:
Day 208 (Month 7)
Reported as:
Geometric mean · Units per milliliter (U/mL)
GMTs for IgG Against Each OspA Serotype
Units per milliliter (U/mL)VLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlacebo
ST1 Day 208278.5 (214.9 to 361.0)274.7 (209.4 to 360.4)21.0 (19.6 to 22.5)
ST2 Day 208545.2 (431.8 to 688.4)579.8 (461.9 to 727.8)20.0 (20.0 to 20.0)
ST3 Day 208520.0 (410.5 to 658.7)596.8 (471.9 to 754.8)20.0 (20.0 to 20.0)
ST4 Day 208332.6 (261.3 to 423.3)367.8 (293.8 to 460.4)21.3 (19.8 to 23.0)
ST5 Day 208332.8 (262.9 to 421.3)358.8 (283.7 to 453.7)20.0 (20.0 to 20.0)
ST6 Day 208339.9 (267.3 to 432.3)345.7 (273.7 to 436.6)21.4 (19.4 to 23.5)
SecondaryGMTs for IgG Against Each OspA Serotype During the Main Study Phase

GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 365 (Month 12) and 545 (Month 18).

Time frame:
At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 365 (Month 12) and Day 545 (Month 18)
Reported as:
Geometric mean · Units per milliliter (U/mL)
GMTs for IgG Against Each OspA Serotype During the Main Study Phase
Units per milliliter (U/mL)VLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlacebo
ST1 Day 121.4 (19.8 to 23.1)20.2 (19.8 to 20.6)21.8 (19.6 to 24.1)
ST1 Day 2922.0 (20.2 to 24.0)20.4 (19.8 to 21.0)22.1 (19.9 to 24.6)
ST1 Day 5722.5 (20.6 to 24.6)21.1 (19.9 to 22.3)21.6 (19.6 to 23.9)
ST1 Day 8564.5 (50.7 to 82.0)75.2 (59.6 to 94.9)21.7 (19.7 to 23.8)
ST1 Day 18026.4 (23.0 to 30.2)24.9 (22.7 to 27.4)21.5 (19.7 to 23.4)
ST1 Day 36548.3 (39.1 to 59.7)37.2 (30.6 to 45.2)21.4 (19.8 to 23.1)
ST1 Day 54529.7 (24.4 to 36.3)23.9 (21.5 to 26.7)20.6 (19.4 to 21.9)
ST2 Day 120.8 (19.9 to 21.8)20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST2 Day 2921.5 (20.2 to 23.0)21.9 (20.2 to 23.6)20.0 (20.0 to 20.0)
ST2 Day 5721.3 (20.0 to 22.6)22.0 (20.1 to 24.0)20.0 (20.0 to 20.0)
ST2 Day 85162.6 (127.0 to 208.2)183.5 (144.9 to 232.4)20.0 (20.0 to 20.0)
ST2 Day 18038.0 (30.9 to 46.5)35.4 (29.9 to 41.9)20.0 (20.0 to 20.0)
ST2 Day 36587.2 (69.0 to 110.2)71.1 (57.0 to 88.8)20.0 (20.0 to 20.0)
ST2 Day 54544.6 (35.9 to 55.4)33.1 (27.5 to 39.7)21.1 (19.0 to 23.4)
ST3 Day 120.3 (19.8 to 20.8)20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST3 Day 2921.3 (20.0 to 22.7)20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST3 Day 5720.9 (19.8 to 22.1)20.7 (19.3 to 22.3)20.0 (20.0 to 20.0)
ST3 Day 85166.3 (128.6 to 215.0)217.7 (171.7 to 275.9)20.7 (19.3 to 22.2)
ST3 Day 18038.2 (31.6 to 46.1)41.0 (34.7 to 48.5)20.4 (19.6 to 21.4)
ST3 Day 36578.5 (62.7 to 98.3)74.6 (59.6 to 93.3)20.0 (20.0 to 20.0)
ST3 Day 54539.1 (31.9 to 48.0)32.2 (27.4 to 37.8)20.0 (20.0 to 20.0)
ST4 Day 120.7 (19.7 to 21.7)20.3 (19.7 to 21.0)20.5 (19.5 to 21.7)
ST4 Day 2920.8 (19.7 to 21.9)20.5 (19.8 to 21.3)20.8 (19.7 to 22.0)
ST4 Day 5721.0 (20.0 to 22.1)20.9 (19.8 to 22.1)21.2 (19.8 to 22.8)
ST4 Day 8579.3 (63.2 to 99.6)100.8 (81.2 to 125.0)21.6 (20.0 to 23.3)
ST4 Day 18028.0 (24.6 to 31.9)27.1 (24.1 to 30.4)21.3 (19.8 to 22.8)
ST4 Day 36553.9 (44.1 to 65.9)43.2 (35.5 to 52.5)21.0 (19.6 to 22.5)
ST4 Day 54535.5 (29.7 to 42.5)27.3 (24.0 to 31.1)22.4 (19.3 to 26.1)
ST5 Day 121.0 (19.9 to 22.2)20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST5 Day 2921.5 (20.0 to 23.1)20.9 (19.8 to 22.0)20.0 (20.0 to 20.0)
ST5 Day 5721.3 (20.0 to 22.7)21.3 (19.9 to 22.9)20.0 (20.0 to 20.0)
ST5 Day 8587.4 (69.1 to 110.5)100.2 (81.0 to 124.1)20.0 (20.0 to 20.0)
ST5 Day 18029.0 (24.9 to 33.8)27.0 (24.1 to 30.3)20.0 (20.0 to 20.0)
ST5 Day 36553.9 (43.5 to 66.9)42.7 (34.9 to 52.2)20.0 (20.0 to 20.0)
ST5 Day 54535.0 (28.9 to 42.4)27.1 (23.8 to 30.9)20.4 (19.6 to 21.2)
ST6 Day 122.6 (20.6 to 24.8)20.7 (19.7 to 21.6)21.2 (19.5 to 23.1)
ST6 Day 2923.3 (20.9 to 25.9)21.2 (20.0 to 22.4)21.0 (19.6 to 22.5)
ST6 Day 5723.2 (21.0 to 25.6)22.2 (20.5 to 24.2)21.6 (19.8 to 23.6)
ST6 Day 8579.9 (62.9 to 101.5)84.3 (67.4 to 105.4)20.7 (19.3 to 22.1)
ST6 Day 18032.7 (27.8 to 38.4)28.8 (25.3 to 32.7)21.7 (19.7 to 23.9)
ST6 Day 36561.1 (48.9 to 76.3)46.7 (37.9 to 57.5)21.5 (19.8 to 23.4)
ST6 Day 54536.8 (30.0 to 45.3)27.1 (23.6 to 31.1)20.7 (19.3 to 22.1)
SecondarySCRs for Each OspA Serotype Specific IgG During the Main Study Phase

Seroconversion Rate (SCR) for each Outer Surface Protein A (OspA) serotype specific IgG ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18). Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): greater than or equal to (\>=) 4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants. Percentages are based on the number of participants with non-missing observations.

Time frame:
Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)
Reported as:
Number · Percentage of Participants
SCRs for Each OspA Serotype Specific IgG During the Main Study Phase
Percentage of ParticipantsVLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlacebo
ST1 Day 292.4 (0.7 to 8.4)1.2 (0.2 to 6.3)2.3 (0.4 to 12.1)
ST1 Day 574.7 (1.8 to 11.5)3.5 (1.2 to 9.8)0.0 (0.0 to 8.2)
ST1 Day 8559.0 (48.3 to 69.0)69.0 (58.5 to 77.9)2.3 (0.4 to 12.1)
ST1 Day 18014.1 (8.3 to 23.1)19.8 (12.7 to 29.4)4.7 (1.3 to 15.5)
ST1 Day 20892.3 (84.2 to 96.4)93.8 (86.2 to 97.3)0.0 (0.0 to 9.2)
ST1 Day 36550.0 (39.4 to 60.6)38.0 (28.1 to 49.0)2.4 (0.4 to 12.3)
ST1 Day 54517.8 (10.7 to 28.1)13.8 (7.5 to 24.3)0.0 (0.0 to 9.2)
ST2 Day 292.4 (0.7 to 8.4)5.8 (2.5 to 12.9)0.0 (0.0 to 8.2)
ST2 Day 571.2 (0.2 to 6.4)5.8 (2.5 to 12.9)0.0 (0.0 to 8.2)
ST2 Day 8584.3 (75.0 to 90.6)89.3 (80.9 to 94.3)0.0 (0.0 to 8.2)
ST2 Day 18032.9 (23.9 to 43.5)38.4 (28.8 to 48.9)0.0 (0.0 to 8.2)
ST2 Day 20896.2 (89.3 to 98.7)98.8 (93.3 to 99.8)0.0 (0.0 to 9.2)
ST2 Day 36572.0 (61.4 to 80.5)70.9 (60.1 to 79.7)0.0 (0.0 to 8.4)
ST2 Day 54545.2 (34.3 to 56.6)35.4 (24.9 to 47.5)2.6 (0.5 to 13.5)
ST3 Day 293.6 (1.2 to 10.1)0.0 (0.0 to 4.3)0.0 (0.0 to 8.2)
ST3 Day 572.4 (0.6 to 8.2)1.2 (0.2 to 6.3)0.0 (0.0 to 8.2)
ST3 Day 8584.3 (75.0 to 90.6)91.7 (83.8 to 95.9)2.3 (0.4 to 12.1)
ST3 Day 18040.0 (30.2 to 50.6)50.0 (39.7 to 60.3)2.3 (0.4 to 12.1)
ST3 Day 20898.7 (93.1 to 99.8)97.5 (91.3 to 99.3)0.0 (0.0 to 9.2)
ST3 Day 36570.7 (60.1 to 79.5)70.9 (60.1 to 79.7)0.0 (0.0 to 8.4)
ST3 Day 54542.5 (31.8 to 53.9)36.9 (26.2 to 49.1)0.0 (0.0 to 9.2)
ST4 Day 291.2 (0.2 to 6.5)1.2 (0.2 to 6.3)2.3 (0.4 to 12.1)
ST4 Day 572.4 (0.6 to 8.2)2.3 (0.6 to 8.1)4.7 (1.3 to 15.5)
ST4 Day 8574.7 (64.4 to 82.8)83.3 (73.9 to 89.8)7.0 (2.4 to 18.6)
ST4 Day 18025.9 (17.8 to 36.1)24.4 (16.6 to 34.5)4.7 (1.3 to 15.5)
ST4 Day 20897.4 (91.1 to 99.3)98.8 (93.3 to 99.8)5.3 (1.5 to 17.3)
ST4 Day 36562.2 (51.4 to 71.9)51.9 (41.1 to 62.6)2.4 (0.4 to 12.3)
ST4 Day 54539.7 (29.3 to 51.2)27.7 (18.3 to 39.6)5.3 (1.5 to 17.3)
ST5 Day 291.2 (0.2 to 6.5)3.5 (1.2 to 9.8)0.0 (0.0 to 8.2)
ST5 Day 571.2 (0.2 to 6.4)4.7 (1.8 to 11.4)0.0 (0.0 to 8.2)
ST5 Day 8573.5 (63.1 to 81.8)81.0 (71.3 to 87.9)0.0 (0.0 to 8.2)
ST5 Day 18020.0 (12.9 to 29.7)25.6 (17.5 to 35.7)0.0 (0.0 to 8.2)
ST5 Day 20894.9 (87.5 to 98.0)96.3 (89.5 to 98.7)0.0 (0.0 to 9.2)
ST5 Day 36553.7 (42.9 to 64.0)48.1 (37.4 to 58.9)0.0 (0.0 to 8.4)
ST5 Day 54534.2 (24.4 to 45.7)27.7 (18.3 to 39.6)2.6 (0.5 to 13.5)
ST6 Day 292.4 (0.7 to 8.4)2.3 (0.6 to 8.1)2.3 (0.4 to 12.1)
ST6 Day 573.5 (1.2 to 9.9)5.8 (2.5 to 12.9)4.7 (1.3 to 15.5)
ST6 Day 8561.4 (50.7 to 71.2)71.4 (61.0 to 80.0)0.0 (0.0 to 8.2)
ST6 Day 18027.1 (18.8 to 37.3)26.7 (18.5 to 36.9)4.7 (1.3 to 15.5)
ST6 Day 20889.7 (81.0 to 94.7)96.3 (89.5 to 98.7)2.6 (0.5 to 13.5)
ST6 Day 36556.1 (45.3 to 66.3)49.4 (38.6 to 60.2)4.8 (1.3 to 15.8)
ST6 Day 54531.5 (22.0 to 42.9)21.5 (13.3 to 33.0)0.0 (0.0 to 9.2)
SecondaryGMFR as Compared to Baseline for IgG Against Each OspA Serotype During the Main Study Phase

Geometric Mean Fold Rise (GMFR) as compared to baseline for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18).

Time frame:
Day 1 (baseline from where comparison was done), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)
Reported as:
Geometric mean · Fold Rise
GMFR as Compared to Baseline for IgG Against Each OspA Serotype During the Main Study Phase
Fold RiseVLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlacebo
ST1 Day 291.0 (1.0 to 1.1)1.0 (1.0 to 1.0)1.0 (1.0 to 1.1)
ST1 Day 571.1 (1.0 to 1.1)1.0 (1.0 to 1.1)1.0 (1.0 to 1.0)
ST1 Day 853.0 (2.4 to 3.8)3.7 (3.0 to 4.7)1.0 (0.9 to 1.1)
ST1 Day 1801.2 (1.1 to 1.4)1.2 (1.1 to 1.4)1.0 (0.9 to 1.1)
ST1 Day 20812.9 (9.8 to 17.1)13.6 (10.4 to 17.8)1.0 (0.9 to 1.0)
ST1 Day 3652.3 (1.8 to 2.8)1.8 (1.5 to 2.2)1.0 (0.9 to 1.1)
ST1 Day 5451.4 (1.1 to 1.7)1.2 (1.1 to 1.3)0.9 (0.9 to 1.0)
ST2 Day 291.0 (1.0 to 1.1)1.1 (1.0 to 1.2)1.0 (1.0 to 1.0)
ST2 Day 571.0 (1.0 to 1.0)1.1 (1.0 to 1.2)1.0 (1.0 to 1.0)
ST2 Day 857.8 (6.1 to 10.0)9.2 (7.2 to 11.6)1.0 (1.0 to 1.0)
ST2 Day 1801.8 (1.5 to 2.2)1.8 (1.5 to 2.1)1.0 (1.0 to 1.0)
ST2 Day 20826.1 (20.4 to 33.3)29.0 (23.1 to 36.4)1.0 (1.0 to 1.0)
ST2 Day 3654.2 (3.3 to 5.3)3.6 (2.8 to 4.4)1.0 (1.0 to 1.0)
ST2 Day 5452.1 (1.7 to 2.6)1.7 (1.4 to 2.0)1.1 (0.9 to 1.2)
ST3 Day 291.1 (1.0 to 1.1)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
ST3 Day 571.0 (1.0 to 1.1)1.0 (1.0 to 1.1)1.0 (1.0 to 1.0)
ST3 Day 858.2 (6.3 to 10.6)10.9 (8.6 to 13.8)1.0 (1.0 to 1.1)
ST3 Day 1801.9 (1.6 to 2.3)2.1 (1.7 to 2.4)1.0 (1.0 to 1.1)
ST3 Day 20825.6 (20.2 to 32.6)29.8 (23.6 to 37.7)1.0 (1.0 to 1.0)
ST3 Day 3653.9 (3.1 to 4.9)3.7 (3.0 to 4.7)1.0 (1.0 to 1.0)
ST3 Day 5452.0 (1.6 to 2.4)1.6 (1.4 to 1.9)1.0 (1.0 to 1.0)
ST4 Day 291.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
ST4 Day 571.0 (1.0 to 1.0)1.0 (1.0 to 1.1)1.0 (1.0 to 1.1)
ST4 Day 853.8 (3.1 to 4.8)5.0 (4.0 to 6.1)1.1 (1.0 to 1.1)
ST4 Day 1801.4 (1.2 to 1.5)1.3 (1.2 to 1.5)1.0 (1.0 to 1.1)
ST4 Day 20816.0 (12.6 to 20.4)18.1 (14.5 to 22.6)1.0 (1.0 to 1.1)
ST4 Day 3652.6 (2.1 to 3.2)2.1 (1.8 to 2.6)1.0 (1.0 to 1.1)
ST4 Day 5451.7 (1.4 to 2.0)1.3 (1.2 to 1.5)1.1 (0.9 to 1.3)
ST5 Day 291.0 (1.0 to 1.1)1.0 (1.0 to 1.1)1.0 (1.0 to 1.0)
ST5 Day 571.0 (1.0 to 1.0)1.1 (1.0 to 1.1)1.0 (1.0 to 1.0)
ST5 Day 854.2 (3.3 to 5.2)5.0 (4.0 to 6.2)1.0 (1.0 to 1.0)
ST5 Day 1801.4 (1.2 to 1.6)1.3 (1.2 to 1.5)1.0 (1.0 to 1.0)
ST5 Day 20815.8 (12.4 to 20.0)17.9 (14.2 to 22.7)1.0 (1.0 to 1.0)
ST5 Day 3652.6 (2.1 to 3.2)2.1 (1.7 to 2.6)1.0 (1.0 to 1.0)
ST5 Day 5451.7 (1.4 to 2.0)1.4 (1.2 to 1.5)1.0 (1.0 to 1.1)
ST6 Day 291.0 (1.0 to 1.1)1.0 (1.0 to 1.1)1.0 (0.9 to 1.1)
ST6 Day 571.0 (1.0 to 1.1)1.1 (1.0 to 1.2)1.0 (0.9 to 1.1)
ST6 Day 853.5 (2.8 to 4.5)4.1 (3.3 to 5.1)1.0 (0.9 to 1.0)
ST6 Day 1801.4 (1.2 to 1.7)1.4 (1.2 to 1.6)1.0 (0.9 to 1.1)
ST6 Day 20814.9 (11.4 to 19.3)16.7 (13.2 to 21.1)1.0 (0.9 to 1.1)
ST6 Day 3652.7 (2.1 to 3.4)2.3 (1.8 to 2.8)1.0 (0.9 to 1.1)
ST6 Day 5451.6 (1.3 to 1.9)1.3 (1.1 to 1.5)1.0 (0.9 to 1.0)
SecondaryGMTs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 18 - 49 Years

GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 18 - 49 years.

Time frame:
At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)
Reported as:
Geometric mean · Units per milliliter (U/mL)
GMTs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 18 - 49 Years
Units per milliliter (U/mL)VLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlacebo
ST1 Day 120.8 (19.3 to 22.4)20.3 (19.7 to 20.9)21.2 (19.5 to 23.1)
ST1 Day 2921.3 (19.5 to 23.4)20.6 (19.8 to 21.5)21.2 (19.5 to 23.1)
ST1 Day 5722.0 (19.9 to 24.3)20.9 (19.9 to 22.0)21.0 (19.6 to 22.5)
ST1 Day 8560.8 (43.6 to 84.8)83.6 (61.7 to 113.2)21.3 (19.5 to 23.2)
ST1 Day 18027.2 (22.7 to 32.5)25.1 (22.2 to 28.4)21.0 (19.6 to 22.6)
ST1 Day 208284.1 (203.4 to 396.9)291.2 (211.6 to 400.8)20.6 (19.4 to 21.9)
ST1 Day 36547.8 (36.4 to 62.7)37.4 (29.7 to 47.1)21.2 (19.5 to 23.1)
ST1 Day 54530.9 (23.3 to 41.0)23.5 (20.6 to 26.6)20.0 (20.0 to 20.0)
ST2 Day 120.4 (19.6 to 21.3)20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST2 Day 2921.5 (19.8 to 23.3)21.7 (19.8 to 23.9)20.0 (20.0 to 20.0)
ST2 Day 5720.9 (19.6 to 22.3)22.5 (19.9 to 25.4)20.0 (20.0 to 20.0)
ST2 Day 85155.9 (113.0 to 215.0)195.1 (145.0 to 262.6)20.0 (20.0 to 20.0)
ST2 Day 18036.6 (28.9 to 46.4)36.0 (29.2 to 44.3)20.0 (20.0 to 20.0)
ST2 Day 208551.9 (419.0 to 727.0)581.3 (465.3 to 726.2)20.0 (20.0 to 20.0)
ST2 Day 36582.6 (62.2 to 109.7)66.1 (51.2 to 85.5)20.0 (20.0 to 20.0)
ST2 Day 54546.3 (35.3 to 60.8)32.3 (26.1 to 39.8)21.6 (18.5 to 25.2)
ST3 Day 120.4 (19.6 to 21.2)20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST3 Day 2921.7 (19.7 to 23.8)20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST3 Day 5721.1 (19.5 to 22.8)21.1 (18.9 to 23.6)20.0 (20.0 to 20.0)
ST3 Day 85178.3 (127.9 to 248.5)233.5 (172.9 to 315.2)21.0 (19.0 to 23.3)
ST3 Day 18040.3 (31.4 to 51.8)42.6 (34.5 to 52.6)20.6 (19.3 to 22.0)
ST3 Day 208573.5 (434.9 to 756.2)633.4 (507.5 to 790.6)20.0 (20.0 to 20.0)
ST3 Day 36580.2 (60.2 to 106.8)71.3 (54.7 to 92.9)20.0 (20.0 to 20.0)
ST3 Day 54540.8 (30.8 to 54.0)33.5 (27.1 to 41.3)20.0 (20.0 to 20.0)
ST4 Day 121.0 (19.6 to 22.6)20.5 (19.5 to 21.5)20.8 (19.2 to 22.4)
ST4 Day 2921.2 (19.5 to 23.0)20.8 (19.7 to 21.9)20.7 (19.3 to 22.1)
ST4 Day 5721.3 (19.8 to 23.0)21.4 (19.7 to 23.2)21.8 (19.7 to 24.1)
ST4 Day 8584.4 (62.1 to 114.5)111.9 (85.1 to 147.2)21.7 (19.8 to 23.9)
ST4 Day 18029.3 (24.5 to 35.2)27.7 (23.8 to 32.2)21.8 (19.7 to 24.1)
ST4 Day 208365.2 (275.1 to 484.8)393.3 (311.9 to 495.8)22.0 (19.7 to 24.5)
ST4 Day 36555.4 (42.7 to 72.0)42.6 (33.9 to 53.4)21.5 (19.4 to 23.8)
ST4 Day 54540.9 (31.8 to 52.6)28.0 (23.7 to 33.0)23.6 (18.9 to 29.5)
ST5 Day 121.1 (19.6 to 22.6)20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST5 Day 2921.9 (19.7 to 24.2)20.4 (19.6 to 21.1)20.0 (20.0 to 20.0)
ST5 Day 5721.5 (19.7 to 23.4)21.3 (19.3 to 23.5)20.0 (20.0 to 20.0)
ST5 Day 8591.0 (66.9 to 123.7)106.4 (81.0 to 139.6)20.0 (20.0 to 20.0)
ST5 Day 18030.0 (24.6 to 36.6)27.1 (23.5 to 31.3)20.0 (20.0 to 20.0)
ST5 Day 208358.8 (269.7 to 477.4)371.0 (287.6 to 478.4)20.0 (20.0 to 20.0)
ST5 Day 36554.5 (40.9 to 72.5)42.0 (33.3 to 53.1)20.0 (20.0 to 20.0)
ST5 Day 54537.7 (28.8 to 49.4)26.8 (22.8 to 31.6)20.6 (19.4 to 21.8)
ST6 Day 123.0 (20.2 to 26.3)20.6 (19.5 to 21.7)21.0 (19.0 to 23.3)
ST6 Day 2924.1 (20.6 to 28.0)21.0 (19.6 to 22.5)20.9 (19.1 to 22.8)
ST6 Day 5723.5 (20.5 to 26.9)22.5 (20.1 to 25.3)21.6 (19.4 to 24.0)
ST6 Day 8586.8 (63.6 to 118.4)85.4 (64.0 to 114.1)21.0 (19.0 to 23.1)
ST6 Day 18032.9 (26.5 to 40.8)27.5 (23.5 to 32.1)21.6 (19.3 to 24.3)
ST6 Day 208362.4 (277.1 to 473.9)337.5 (258.2 to 441.1)21.2 (18.8 to 23.8)
ST6 Day 36561.2 (45.9 to 81.8)41.7 (32.7 to 53.2)21.6 (19.3 to 24.1)
ST6 Day 54541.1 (30.7 to 55.0)24.7 (21.2 to 28.9)21.0 (19.0 to 23.1)
SecondaryGMTs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 50 - 65 Years

GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 50 - 65 years.

Time frame:
At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)
Reported as:
Geometric mean · Units per milliliter (U/mL)
GMTs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 50 - 65 Years
Units per milliliter (U/mL)VLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlacebo
ST1 Day 122.6 (19.0 to 26.8)20.0 (20.0 to 20.0)23.1 (16.9 to 31.5)
ST1 Day 2923.3 (19.6 to 27.8)20.0 (20.0 to 20.0)24.4 (17.7 to 33.8)
ST1 Day 5723.5 (19.5 to 28.3)21.4 (18.6 to 24.6)23.2 (16.8 to 31.9)
ST1 Day 8571.5 (51.2 to 100.0)61.6 (42.8 to 88.5)22.6 (17.3 to 29.6)
ST1 Day 18024.9 (20.1 to 30.9)24.5 (20.9 to 28.6)22.5 (17.4 to 29.1)
ST1 Day 208269.3 (174.1 to 416.5)246.6 (145.6 to 417.5)21.9 (18.0 to 26.6)
ST1 Day 36549.2 (34.4 to 70.4)36.8 (25.3 to 53.4)21.8 (18.1 to 26.2)
ST1 Day 54527.9 (21.4 to 36.5)24.8 (20.1 to 30.5)21.9 (17.9 to 26.9)
ST2 Day 121.6 (19.3 to 24.2)20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST2 Day 2921.7 (19.3 to 24.4)22.1 (19.0 to 25.7)20.0 (20.0 to 20.0)
ST2 Day 5721.9 (19.2 to 25.0)21.1 (18.9 to 23.5)20.0 (20.0 to 20.0)
ST2 Day 85175.3 (117.0 to 262.6)163.4 (108.4 to 246.1)20.0 (20.0 to 20.0)
ST2 Day 18040.5 (27.2 to 60.4)34.3 (25.4 to 46.3)20.0 (20.0 to 20.0)
ST2 Day 208534.1 (342.5 to 832.8)577.0 (340.7 to 977.2)20.0 (20.0 to 20.0)
ST2 Day 36595.9 (62.4 to 147.5)80.6 (52.4 to 124.2)20.0 (20.0 to 20.0)
ST2 Day 54541.9 (28.5 to 61.7)34.5 (23.9 to 49.7)20.0 (20.0 to 20.0)
ST3 Day 120.0 (20.0 to 20.0)20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST3 Day 2920.6 (19.4 to 21.9)20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST3 Day 5720.6 (19.4 to 21.8)20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST3 Day 85147.1 (96.3 to 224.7)190.6 (127.1 to 285.7)20.0 (20.0 to 20.0)
ST3 Day 18034.5 (25.8 to 46.2)38.1 (28.4 to 51.0)20.0 (20.0 to 20.0)
ST3 Day 208440.6 (281.3 to 690.1)534.3 (307.0 to 930.0)20.0 (20.0 to 20.0)
ST3 Day 36575.7 (51.5 to 111.2)80.6 (52.7 to 123.4)20.0 (20.0 to 20.0)
ST3 Day 54536.6 (27.0 to 49.7)30.1 (23.1 to 39.1)20.0 (20.0 to 20.0)
ST4 Day 120.0 (20.0 to 20.0)20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST4 Day 2920.0 (20.0 to 20.0)20.0 (20.0 to 20.0)21.1 (18.8 to 23.7)
ST4 Day 5720.5 (19.5 to 21.7)20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST4 Day 8571.1 (50.4 to 100.3)82.6 (57.9 to 117.7)21.3 (18.6 to 24.3)
ST4 Day 18025.7 (21.8 to 30.3)25.9 (21.6 to 31.0)20.0 (20.0 to 20.0)
ST4 Day 208283.9 (179.8 to 448.3)324.8 (197.4 to 534.3)20.0 (20.0 to 20.0)
ST4 Day 36551.4 (37.0 to 71.4)44.3 (30.2 to 64.8)20.0 (20.0 to 20.0)
ST4 Day 54528.3 (22.6 to 35.5)26.3 (21.2 to 32.7)20.0 (20.0 to 20.0)
ST5 Day 120.9 (19.1 to 22.8)20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST5 Day 2920.8 (19.2 to 22.7)21.9 (19.0 to 25.3)20.0 (20.0 to 20.0)
ST5 Day 5720.9 (19.1 to 23.0)21.4 (19.4 to 23.7)20.0 (20.0 to 20.0)
ST5 Day 8581.4 (55.9 to 118.5)89.6 (62.6 to 128.2)20.0 (20.0 to 20.0)
ST5 Day 18027.3 (21.3 to 34.9)26.7 (21.8 to 32.8)20.0 (20.0 to 20.0)
ST5 Day 208293.1 (190.5 to 451.0)337.2 (204.3 to 556.6)20.0 (20.0 to 20.0)
ST5 Day 36552.9 (37.7 to 74.4)43.8 (29.7 to 64.6)20.0 (20.0 to 20.0)
ST5 Day 54531.0 (23.9 to 40.3)27.6 (21.7 to 35.0)20.0 (20.0 to 20.0)
ST6 Day 121.8 (19.3 to 24.8)20.9 (19.1 to 22.8)21.7 (18.1 to 26.1)
ST6 Day 2922.0 (19.2 to 25.1)21.5 (19.4 to 23.8)21.3 (18.6 to 24.3)
ST6 Day 5722.7 (19.6 to 26.4)21.7 (19.3 to 24.3)21.7 (18.2 to 25.9)
ST6 Day 8569.0 (46.8 to 101.9)82.1 (56.8 to 118.7)20.0 (20.0 to 20.0)
ST6 Day 18032.3 (25.2 to 41.4)31.6 (25.0 to 39.9)21.9 (18.0 to 26.7)
ST6 Day 208305.1 (188.3 to 494.3)361.4 (225.9 to 578.3)21.8 (18.0 to 26.4)
ST6 Day 36560.7 (42.0 to 87.9)56.6 (38.3 to 83.7)21.4 (18.5 to 24.6)
ST6 Day 54530.9 (23.5 to 40.8)31.6 (24.1 to 41.4)20.0 (20.0 to 20.0)
SecondarySCR for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 18 - 49 Years

SCR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 18 - 49 years. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): \>=4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants.

Time frame:
Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)
Reported as:
Number · Percentage of Participants
SCR for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 18 - 49 Years
Percentage of ParticipantsVLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlacebo
ST1 Day 291.9 (0.3 to 9.9)1.8 (0.3 to 9.3)0.0 (0.0 to 11.4)
ST1 Day 575.5 (1.9 to 14.9)3.5 (1.0 to 11.9)0.0 (0.0 to 11.4)
ST1 Day 8554.7 (41.5 to 67.3)70.9 (57.9 to 81.2)3.3 (0.6 to 16.7)
ST1 Day 18018.2 (10.2 to 30.3)19.3 (11.1 to 31.3)6.7 (1.8 to 21.3)
ST1 Day 20893.9 (83.5 to 97.9)94.2 (84.4 to 98.0)0.0 (0.0 to 12.9)
ST1 Day 36551.9 (38.7 to 64.9)38.0 (25.9 to 51.8)3.4 (0.6 to 17.2)
ST1 Day 54520.0 (10.9 to 33.8)12.2 (5.3 to 25.5)0.0 (0.0 to 12.9)
ST2 Day 293.8 (1.0 to 12.8)5.3 (1.8 to 14.4)0.0 (0.0 to 11.4)
ST2 Day 571.8 (0.3 to 9.6)7.0 (2.8 to 16.7)0.0 (0.0 to 11.4)
ST2 Day 8584.9 (72.9 to 92.1)90.9 (80.4 to 96.1)0.0 (0.0 to 11.4)
ST2 Day 18034.5 (23.4 to 47.7)38.6 (27.1 to 51.6)0.0 (0.0 to 11.4)
ST2 Day 208100 (92.7 to 100)100 (93.1 to 100)0.0 (0.0 to 12.9)
ST2 Day 36573.1 (59.7 to 83.2)70.0 (56.2 to 80.9)0.0 (0.0 to 11.7)
ST2 Day 54553.3 (39.1 to 67.1)36.6 (23.6 to 51.9)3.8 (0.7 to 18.9)
ST3 Day 293.8 (1.0 to 12.8)0.0 (0.0 to 6.3)0.0 (0.0 to 11.4)
ST3 Day 571.8 (0.3 to 9.6)1.8 (0.3 to 9.3)0.0 (0.0 to 11.4)
ST3 Day 8584.9 (72.9 to 92.1)92.7 (82.7 to 97.1)3.3 (0.6 to 16.7)
ST3 Day 18041.8 (29.7 to 55.0)52.6 (39.9 to 65.0)3.3 (0.6 to 16.7)
ST3 Day 208100 (92.7 to 100)100 (93.1 to 100)0.0 (0.0 to 12.9)
ST3 Day 36569.2 (55.7 to 80.1)72.0 (58.3 to 82.5)0.0 (0.0 to 11.7)
ST3 Day 54542.2 (29.0 to 56.7)39.0 (25.7 to 54.3)0.0 (0.0 to 12.9)
ST4 Day 291.9 (0.3 to 9.9)1.8 (0.3 to 9.3)0.0 (0.0 to 11.4)
ST4 Day 571.8 (0.3 to 9.6)3.5 (1.0 to 11.9)6.7 (1.8 to 21.3)
ST4 Day 8575.5 (62.4 to 85.1)87.3 (76.0 to 93.7)6.7 (1.8 to 21.3)
ST4 Day 18025.5 (15.8 to 38.3)24.6 (15.2 to 37.1)6.7 (1.8 to 21.3)
ST4 Day 208100 (92.7 to 100)100 (93.1 to 100)7.7 (2.1 to 24.1)
ST4 Day 36561.5 (48.0 to 73.5)52.0 (38.5 to 65.2)3.4 (0.6 to 17.2)
ST4 Day 54546.7 (32.9 to 60.9)29.3 (17.6 to 44.5)7.7 (2.1 to 24.1)
ST5 Day 291.9 (0.3 to 9.9)1.8 (0.3 to 9.3)0.0 (0.0 to 11.4)
ST5 Day 571.8 (0.3 to 9.6)3.5 (1.0 to 11.9)0.0 (0.0 to 11.4)
ST5 Day 8573.6 (60.4 to 83.6)81.8 (69.7 to 89.8)0.0 (0.0 to 11.4)
ST5 Day 18021.8 (12.9 to 34.4)26.3 (16.6 to 39.0)0.0 (0.0 to 11.4)
ST5 Day 20895.9 (86.3 to 98.9)98.1 (89.9 to 99.7)0.0 (0.0 to 12.9)
ST5 Day 36551.9 (38.7 to 64.9)48.0 (34.8 to 61.5)0.0 (0.0 to 11.7)
ST5 Day 54537.8 (25.1 to 52.4)26.8 (15.7 to 41.9)3.8 (0.7 to 18.9)
ST6 Day 293.8 (1.0 to 12.8)1.8 (0.3 to 9.3)0.0 (0.0 to 11.4)
ST6 Day 573.6 (1.0 to 12.3)7.0 (2.8 to 16.7)3.3 (0.6 to 16.7)
ST6 Day 8562.3 (48.8 to 74.1)70.9 (57.9 to 81.2)0.0 (0.0 to 11.4)
ST6 Day 18025.5 (15.8 to 38.3)22.8 (13.8 to 35.2)3.3 (0.6 to 16.7)
ST6 Day 20889.8 (78.2 to 95.6)96.2 (87.0 to 98.9)0.0 (0.0 to 12.9)
ST6 Day 36555.8 (42.3 to 68.4)44.0 (31.2 to 57.7)3.4 (0.6 to 17.2)
ST6 Day 54537.8 (25.1 to 52.4)14.6 (6.9 to 28.4)0.0 (0.0 to 12.9)
SecondarySCR for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 50 - 65 Years

SCR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 50 - 65 years. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): \>=4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants.

Time frame:
Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)
Reported as:
Number · Percentage of Participants
SCR for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 50 - 65 Years
Percentage of ParticipantsVLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlacebo
ST1 Day 293.3 (0.6 to 16.7)0.0 (0.0 to 11.7)7.7 (1.4 to 33.3)
ST1 Day 573.3 (0.6 to 16.7)3.4 (0.6 to 17.2)0.0 (0.0 to 22.8)
ST1 Day 8566.7 (48.8 to 80.8)65.5 (47.3 to 80.1)0.0 (0.0 to 22.8)
ST1 Day 1806.7 (1.8 to 21.3)20.7 (9.8 to 38.4)0.0 (0.0 to 22.8)
ST1 Day 20889.7 (73.6 to 96.4)92.9 (77.4 to 98.0)0.0 (0.0 to 24.2)
ST1 Day 36546.7 (30.2 to 63.9)37.9 (22.7 to 56.0)0.0 (0.0 to 22.8)
ST1 Day 54514.3 (5.7 to 31.5)16.7 (6.7 to 35.9)0.0 (0.0 to 24.2)
ST2 Day 290.0 (0.0 to 11.4)6.9 (1.9 to 22.0)0.0 (0.0 to 22.8)
ST2 Day 570.0 (0.0 to 11.4)3.4 (0.6 to 17.2)0.0 (0.0 to 22.8)
ST2 Day 8583.3 (66.4 to 92.7)86.2 (69.4 to 94.5)0.0 (0.0 to 22.8)
ST2 Day 18030.0 (16.7 to 47.9)37.9 (22.7 to 56.0)0.0 (0.0 to 22.8)
ST2 Day 20889.7 (73.6 to 96.4)96.4 (82.3 to 99.4)0.0 (0.0 to 24.2)
ST2 Day 36570.0 (52.1 to 83.3)72.4 (54.3 to 85.3)0.0 (0.0 to 22.8)
ST2 Day 54532.1 (17.9 to 50.7)33.3 (18.0 to 53.3)0.0 (0.0 to 24.2)
ST3 Day 293.3 (0.6 to 16.7)0.0 (0.0 to 11.7)0.0 (0.0 to 22.8)
ST3 Day 573.3 (0.6 to 16.7)0.0 (0.0 to 11.7)0.0 (0.0 to 22.8)
ST3 Day 8583.3 (66.4 to 92.7)89.7 (73.6 to 96.4)0.0 (0.0 to 22.8)
ST3 Day 18036.7 (21.9 to 54.5)44.8 (28.4 to 62.5)0.0 (0.0 to 22.8)
ST3 Day 20896.6 (82.8 to 99.4)92.9 (77.4 to 98.0)0.0 (0.0 to 24.2)
ST3 Day 36573.3 (55.6 to 85.8)69.0 (50.8 to 82.7)0.0 (0.0 to 22.8)
ST3 Day 54542.9 (26.5 to 60.9)33.3 (18.0 to 53.3)0.0 (0.0 to 24.2)
ST4 Day 290.0 (0.0 to 11.4)0.0 (0.0 to 11.7)7.7 (1.4 to 33.3)
ST4 Day 573.3 (0.6 to 16.7)0.0 (0.0 to 11.7)0.0 (0.0 to 22.8)
ST4 Day 8573.3 (55.6 to 85.8)75.9 (57.9 to 87.8)7.7 (1.4 to 33.3)
ST4 Day 18026.7 (14.2 to 44.4)24.1 (12.2 to 42.1)0.0 (0.0 to 22.8)
ST4 Day 20893.1 (78.0 to 98.1)96.4 (82.3 to 99.4)0.0 (0.0 to 24.2)
ST4 Day 36563.3 (45.5 to 78.1)51.7 (34.4 to 68.6)0.0 (0.0 to 22.8)
ST4 Day 54528.6 (15.3 to 47.1)25.0 (12.0 to 44.9)0.0 (0.0 to 24.2)
ST5 Day 290.0 (0.0 to 11.4)6.9 (1.9 to 22.0)0.0 (0.0 to 22.8)
ST5 Day 570.0 (0.0 to 11.4)6.9 (1.9 to 22.0)0.0 (0.0 to 22.8)
ST5 Day 8573.3 (55.6 to 85.8)79.3 (61.6 to 90.2)0.0 (0.0 to 22.8)
ST5 Day 18016.7 (7.3 to 33.6)24.1 (12.2 to 42.1)0.0 (0.0 to 22.8)
ST5 Day 20893.1 (78.0 to 98.1)92.9 (77.4 to 98.0)0.0 (0.0 to 24.2)
ST5 Day 36556.7 (39.2 to 72.6)48.3 (31.4 to 65.6)0.0 (0.0 to 22.8)
ST5 Day 54528.6 (15.3 to 47.1)29.2 (14.9 to 49.2)0.0 (0.0 to 24.2)
ST6 Day 290.0 (0.0 to 11.4)3.4 (0.6 to 17.2)7.7 (1.4 to 33.3)
ST6 Day 573.3 (0.6 to 16.7)3.4 (0.6 to 17.2)7.7 (1.4 to 33.3)
ST6 Day 8560.0 (42.3 to 75.4)72.4 (54.3 to 85.3)0.0 (0.0 to 22.8)
ST6 Day 18030.0 (16.7 to 47.9)34.5 (19.9 to 52.7)7.7 (1.4 to 33.3)
ST6 Day 20889.7 (73.6 to 96.4)96.4 (82.3 to 99.4)8.3 (1.5 to 35.4)
ST6 Day 36556.7 (39.2 to 72.6)58.6 (40.7 to 74.5)7.7 (1.4 to 33.3)
ST6 Day 54521.4 (10.2 to 39.5)33.3 (18.0 to 53.3)0.0 (0.0 to 24.2)
SecondaryGMFRs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 18 - 49 Years

GMFR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 18 - 49 years.

Time frame:
Day 1 (baseline), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)
Reported as:
Geometric mean · Fold Rise
GMFRs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 18 - 49 Years
Fold RiseVLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlacebo
ST1 Day 291.0 (1.0 to 1.1)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
ST1 Day 571.1 (1.0 to 1.1)1.0 (1.0 to 1.1)1.0 (1.0 to 1.0)
ST1 Day 852.9 (2.1 to 4.1)4.1 (3.0 to 5.6)1.0 (0.9 to 1.1)
ST1 Day 1801.3 (1.1 to 1.6)1.2 (1.1 to 1.4)1.0 (0.9 to 1.1)
ST1 Day 20813.6 (9.7 to 19.2)14.3 (10.4 to 19.7)1.0 (0.9 to 1.0)
ST1 Day 3652.3 (1.8 to 3.0)1.8 (1.5 to 2.3)1.0 (0.9 to 1.1)
ST1 Day 5451.5 (1.1 to 1.9)1.1 (1.0 to 1.3)0.9 (0.8 to 1.0)
ST2 Day 291.1 (1.0 to 1.1)1.1 (1.0 to 1.2)1.0 (1.0 to 1.0)
ST2 Day 571.0 (1.0 to 1.1)1.1 (1.0 to 1.3)1.0 (1.0 to 1.0)
ST2 Day 857.6 (5.5 to 10.5)9.8 (7.2 to 13.1)1.0 (1.0 to 1.0)
ST2 Day 1801.8 (1.4 to 2.3)1.8 (1.5 to 2.2)1.0 (1.0 to 1.0)
ST2 Day 20827.0 (20.5 to 35.5)29.1 (23.3 to 36.3)1.0 (1.0 to 1.0)
ST2 Day 3654.0 (3.0 to 5.4)3.3 (2.6 to 4.3)1.0 (1.0 to 1.0)
ST2 Day 5452.3 (1.7 to 2.9)1.6 (1.3 to 2.0)1.1 (0.9 to 1.3)
ST3 Day 291.1 (1.0 to 1.1)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
ST3 Day 571.0 (1.0 to 1.1)1.1 (0.9 to 1.2)1.0 (1.0 to 1.0)
ST3 Day 858.7 (6.2 to 12.2)11.7 (8.6 to 15.8)1.1 (0.9 to 1.2)
ST3 Day 1802.0 (1.5 to 2.5)2.1 (1.7 to 2.6)1.0 (1.0 to 1.1)
ST3 Day 20828.1 (21.1 to 37.3)31.7 (25.4 to 39.5)1.0 (1.0 to 1.0)
ST3 Day 3653.9 (2.9 to 5.2)3.6 (2.7 to 4.6)1.0 (1.0 to 1.0)
ST3 Day 5452.0 (1.5 to 2.7)1.7 (1.4 to 2.1)1.0 (1.0 to 1.0)
ST4 Day 291.0 (0.9 to 1.1)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
ST4 Day 571.0 (1.0 to 1.0)1.0 (1.0 to 1.1)1.0 (1.0 to 1.1)
ST4 Day 854.0 (3.0 to 5.4)5.5 (4.2 to 7.1)1.0 (1.0 to 1.1)
ST4 Day 1801.4 (1.2 to 1.7)1.4 (1.2 to 1.6)1.1 (1.0 to 1.1)
ST4 Day 20817.2 (13.0 to 22.9)19.1 (15.3 to 24.0)1.1 (1.0 to 1.1)
ST4 Day 3652.6 (2.0 to 3.4)2.1 (1.7 to 2.6)1.0 (1.0 to 1.1)
ST4 Day 5451.9 (1.5 to 2.5)1.4 (1.2 to 1.6)1.1 (0.9 to 1.4)
ST5 Day 291.0 (1.0 to 1.1)1.0 (1.0 to 1.1)1.0 (1.0 to 1.0)
ST5 Day 571.0 (1.0 to 1.1)1.1 (1.0 to 1.2)1.0 (1.0 to 1.0)
ST5 Day 854.3 (3.2 to 5.8)5.3 (4.1 to 7.0)1.0 (1.0 to 1.0)
ST5 Day 1801.4 (1.2 to 1.7)1.4 (1.2 to 1.6)1.0 (1.0 to 1.0)
ST5 Day 20816.9 (12.6 to 22.8)18.5 (14.4 to 23.9)1.0 (1.0 to 1.0)
ST5 Day 3652.6 (1.9 to 3.4)2.1 (1.7 to 2.7)1.0 (1.0 to 1.0)
ST5 Day 5451.8 (1.4 to 2.3)1.3 (1.1 to 1.6)1.0 (1.0 to 1.1)
ST6 Day 291.0 (1.0 to 1.1)1.0 (1.0 to 1.1)1.0 (1.0 to 1.0)
ST6 Day 571.0 (1.0 to 1.1)1.1 (1.0 to 1.2)1.0 (1.0 to 1.1)
ST6 Day 853.7 (2.7 to 5.1)4.2 (3.1 to 5.5)1.0 (1.0 to 1.0)
ST6 Day 1801.4 (1.2 to 1.8)1.3 (1.2 to 1.5)1.0 (1.0 to 1.1)
ST6 Day 20815.5 (11.1 to 21.4)16.4 (12.5 to 21.4)1.0 (1.0 to 1.0)
ST6 Day 3652.6 (1.9 to 3.6)2.0 (1.6 to 2.5)1.0 (1.0 to 1.1)
ST6 Day 5451.7 (1.3 to 2.3)1.2 (1.0 to 1.4)1.0 (1.0 to 1.0)
SecondaryGMFRs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 50 - 65 Years

GMFR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 50 - 65 years.

Time frame:
Day 1 (baseline), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)
Reported as:
Geometric mean · Fold Rise
GMFRs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 50 - 65 Years
Fold RiseVLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlacebo
ST1 Day 291.0 (0.9 to 1.1)1.0 (1.0 to 1.0)1.1 (0.9 to 1.2)
ST1 Day 571.0 (0.9 to 1.1)1.1 (0.9 to 1.2)1.0 (1.0 to 1.0)
ST1 Day 853.2 (2.3 to 4.5)3.1 (2.1 to 4.4)1.0 (0.9 to 1.0)
ST1 Day 1801.1 (1.0 to 1.3)1.2 (1.0 to 1.4)1.0 (0.9 to 1.0)
ST1 Day 20811.9 (7.2 to 19.5)12.3 (7.3 to 20.9)0.9 (0.8 to 1.1)
ST1 Day 3652.2 (1.5 to 3.1)1.8 (1.3 to 2.7)0.9 (0.8 to 1.1)
ST1 Day 5451.2 (1.0 to 1.5)1.2 (1.0 to 1.5)0.9 (0.8 to 1.1)
ST2 Day 291.0 (1.0 to 1.0)1.1 (1.0 to 1.3)1.0 (1.0 to 1.0)
ST2 Day 571.0 (1.0 to 1.0)1.1 (0.9 to 1.2)1.0 (1.0 to 1.0)
ST2 Day 858.1 (5.3 to 12.5)8.2 (5.4 to 12.3)1.0 (1.0 to 1.0)
ST2 Day 1801.9 (1.3 to 2.8)1.7 (1.3 to 2.3)1.0 (1.0 to 1.0)
ST2 Day 20824.6 (15.1 to 40.0)28.8 (17.0 to 48.9)1.0 (1.0 to 1.0)
ST2 Day 3654.4 (2.9 to 6.9)4.0 (2.6 to 6.2)1.0 (1.0 to 1.0)
ST2 Day 5451.9 (1.3 to 2.8)1.7 (1.2 to 2.5)1.0 (1.0 to 1.0)
ST3 Day 291.0 (1.0 to 1.1)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
ST3 Day 571.0 (1.0 to 1.1)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
ST3 Day 857.4 (4.8 to 11.2)9.5 (6.4 to 14.3)1.0 (1.0 to 1.0)
ST3 Day 1801.7 (1.3 to 2.3)1.9 (1.4 to 2.6)1.0 (1.0 to 1.0)
ST3 Day 20822.0 (14.1 to 34.5)26.7 (15.4 to 46.5)1.0 (1.0 to 1.0)
ST3 Day 3653.8 (2.6 to 5.6)4.0 (2.6 to 6.2)1.0 (1.0 to 1.0)
ST3 Day 5451.8 (1.4 to 2.5)1.5 (1.2 to 2.0)1.0 (1.0 to 1.0)
ST4 Day 291.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.1 (0.9 to 1.2)
ST4 Day 571.0 (1.0 to 1.1)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
ST4 Day 853.6 (2.5 to 5.0)4.1 (2.9 to 5.9)1.1 (0.9 to 1.2)
ST4 Day 1801.3 (1.1 to 1.5)1.3 (1.1 to 1.5)1.0 (1.0 to 1.0)
ST4 Day 20814.2 (9.0 to 22.4)16.2 (9.9 to 26.7)1.0 (1.0 to 1.0)
ST4 Day 3652.6 (1.8 to 3.6)2.2 (1.5 to 3.2)1.0 (1.0 to 1.0)
ST4 Day 5451.4 (1.1 to 1.8)1.3 (1.1 to 1.6)1.0 (1.0 to 1.0)
ST5 Day 291.0 (1.0 to 1.0)1.1 (0.9 to 1.3)1.0 (1.0 to 1.0)
ST5 Day 571.0 (1.0 to 1.0)1.1 (1.0 to 1.2)1.0 (1.0 to 1.0)
ST5 Day 853.9 (2.7 to 5.6)4.5 (3.1 to 6.4)1.0 (1.0 to 1.0)
ST5 Day 1801.3 (1.0 to 1.6)1.3 (1.1 to 1.6)1.0 (1.0 to 1.0)
ST5 Day 20814.0 (9.3 to 21.2)16.9 (10.2 to 27.8)1.0 (1.0 to 1.0)
ST5 Day 3652.5 (1.8 to 3.5)2.2 (1.5 to 3.2)1.0 (1.0 to 1.0)
ST5 Day 5451.5 (1.2 to 1.9)1.4 (1.1 to 1.8)1.0 (1.0 to 1.0)
ST6 Day 291.0 (1.0 to 1.0)1.0 (1.0 to 1.1)1.0 (0.8 to 1.2)
ST6 Day 571.0 (1.0 to 1.1)1.0 (1.0 to 1.1)1.0 (0.8 to 1.3)
ST6 Day 853.2 (2.2 to 4.5)3.9 (2.7 to 5.7)0.9 (0.8 to 1.1)
ST6 Day 1801.5 (1.2 to 1.8)1.5 (1.2 to 1.9)1.0 (0.8 to 1.3)
ST6 Day 20813.9 (8.7 to 22.2)17.3 (10.7 to 28.0)1.0 (0.7 to 1.3)
ST6 Day 3652.8 (1.9 to 4.0)2.7 (1.8 to 4.0)1.0 (0.8 to 1.2)
ST6 Day 5451.4 (1.1 to 1.8)1.5 (1.2 to 2.0)0.9 (0.7 to 1.1)
SecondaryPercentage of Participants With Serious Adverse Events (SAEs) During the Main Study Phase

SAE was any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. Two-sided 95% confidence intervals were calculated according to Altman method.

Time frame:
From Day 1 of vaccination up to Day 545 (Month 18)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Serious Adverse Events (SAEs) During the Main Study Phase
Percentage of ParticipantsVLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlacebo
Percentage of Participants With Serious Adverse Events (SAEs) During the Main Study Phase4.1 (1.6 to 10.1)4.1 (1.6 to 10.0)3.9 (1.1 to 13.2)
SecondaryPercentage of Participants With Related SAEs During the Main Study Phase

SAE was any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.

Time frame:
From Day 1 of vaccination up to Day 545 (Month 18)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Related SAEs During the Main Study Phase
Percentage of ParticipantsVLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlacebo
Percentage of Participants With Related SAEs During the Main Study Phase0.0 (0.0 to 3.8)0.0 (0.0 to 3.8)0.0 (0.0 to 7.0)
SecondaryPercentage of Participants Adverse Event of Special Interest (AESIs) During the Main Study Phase

AESIs were defined as serious or non-serious AEs which were of scientific and medical concern specific to the investigational product. Two-sided 95% confidence intervals were calculated according to Altman method.

Time frame:
From Day 1 of vaccination up to Day 545 (Month 18)
Reported as:
Number · Percentage of Participants
Percentage of Participants Adverse Event of Special Interest (AESIs) During the Main Study Phase
Percentage of ParticipantsVLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlacebo
Percentage of Participants Adverse Event of Special Interest (AESIs) During the Main Study Phase2.1 (0.6 to 7.2)0.0 (0.0 to 3.8)0.0 (0.0 to 7.0)
SecondaryPercentage of Participants With Related AESIs During the Main Study Phase

AESIs were defined as serious or non-serious AEs which were of scientific and medical concern specific to the investigational product. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.

Time frame:
From Day 1 of vaccination up to Day 545 (Month 18)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Related AESIs During the Main Study Phase
Percentage of ParticipantsVLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlacebo
Percentage of Participants With Related AESIs During the Main Study Phase1.0 (0.2 to 5.6)0.0 (0.0 to 3.8)0.0 (0.0 to 7.0)
SecondaryPercentage of Participants With Unsolicited AEs During the Main Study Phase

An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant temporally associated with the use of investigational product, whether or not related to investigational product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up (more than 6 days after vaccination) for solicited symptoms. Two-sided 95% confidence intervals were calculated according to Altman method.

Time frame:
From Day 1 of vaccination up to Day 545 (Month 18)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Unsolicited AEs During the Main Study Phase
Percentage of ParticipantsVLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlacebo
Percentage of Participants With Unsolicited AEs During the Main Study Phase66.0 (56.1 to 74.6)64.3 (54.4 to 73.1)68.6 (55.0 to 79.7)
SecondaryPercentage of Participants With Related Unsolicited AEs During the Main Study Phase

An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant temporally associated with the use of investigational product, whether or not related to investigational product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up (more than 6 days after vaccination) for solicited symptoms. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.

Time frame:
From Day 1 of vaccination up to Day 545 (Month 18)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Related Unsolicited AEs During the Main Study Phase
Percentage of ParticipantsVLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlacebo
Percentage of Participants With Related Unsolicited AEs During the Main Study Phase18.6 (12.1 to 27.4)22.4 (15.3 to 31.7)7.8 (3.1 to 18.5)
SecondaryPercentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Each and After Any Vaccination During the Main Study Phase

Solicited local AEs included pain, tenderness, induration (hardening), swelling and erythema (redness). Solicited systemic AEs included headache, myalgia (muscle pain), arthralgia (joint pain), fever (oral body temperature), flu-like symptoms, nausea, vomiting and fatigue. Two-sided 95% confidence intervals were calculated according to Altman method.

Time frame:
Up to 7 days after Vaccination 1, 2 and 3; Up to 7 days after any vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Each and After Any Vaccination During the Main Study Phase
Percentage of ParticipantsVLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlacebo
Any solicited local AE: Any vaccination95.9 (89.9 to 98.4)98.0 (92.9 to 99.4)45.1 (32.3 to 58.6)
Solicited local AE: 1st vaccination94.8 (88.5 to 97.8)93.9 (87.3 to 97.2)25.5 (15.5 to 38.9)
Solicited local AE: 2nd vaccination80.4 (71.4 to 87.1)83.7 (75.1 to 89.7)23.5 (14.0 to 36.8)
Solicited local AE: 3rd vaccination78.4 (69.2 to 85.4)82.7 (74.0 to 88.9)17.6 (9.6 to 30.3)
Any solicited systemic AE: Any vaccination78.4 (69.2 to 85.4)69.4 (59.7 to 77.6)51.0 (37.7 to 64.1)
Solicited systemic AE: 1st vaccination61.9 (51.9 to 70.9)56.1 (46.3 to 65.5)35.3 (23.6 to 49.0)
Solicited systemic AE: 2nd vaccination47.4 (37.8 to 57.3)40.8 (31.6 to 50.7)21.6 (12.5 to 34.6)
Solicited systemic AE: 3rd vaccination36.1 (27.2 to 46.0)40.8 (31.6 to 50.7)17.6 (9.6 to 30.3)
SecondaryPercentage of Participants With SAEs, AESIs, Solicited and Unsolicited AEs Stratified by Age Group During the Main Study Phase

Percentage of participants with SAEs, AESIs, solicited and unsolicited AEs during main study phase stratified by age group 18-49 years and 50-65 years were reported. SAE: any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. AESI: any AEs of scientific/medical concern specific to study vaccine. Solicited AE: predefined reactions at injection site or systemic reactions after each vaccination. Unsolicited AE: any untoward medical occurrence in participant associated with use of study vaccine, whether or not related to study vaccine, reported in addition to solicited and any solicited symptom with onset outside specified period of follow-up. Two-sided 95% confidence intervals were calculated according to Altman method.

Time frame:
From Day 1 of vaccination up to Day 545 (Month 18)
Reported as:
Number · Percentage of Participants
Percentage of Participants With SAEs, AESIs, Solicited and Unsolicited AEs Stratified by Age Group During the Main Study Phase
Percentage of ParticipantsVLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlacebo
SAE: 18-49 Years3.1 (0.9 to 10.7)3.1 (0.9 to 10.7)0.0 (0.0 to 10.7)
SAE: 50-65 Years6.1 (1.7 to 19.6)5.9 (1.6 to 19.1)10.5 (2.9 to 31.4)
AESI: 18-49 Years3.1 (0.9 to 10.7)0.0 (0.0 to 5.7)0.0 (0.0 to 10.7)
AESI: 50-65 Years0.0 (0.0 to 10.4)0.0 (0.0 to 10.2)0.0 (0.0 to 16.8)
Solicited AE: 18-49 Years95.3 (87.1 to 98.4)96.9 (89.3 to 99.1)59.4 (42.3 to 74.5)
Solicited AE: 50-65 Years100 (89.6 to 100)100 (89.8 to 100)73.7 (51.2 to 88.2)
Unsolicited AE: 18-49 Years64.1 (51.8 to 74.7)65.6 (53.4 to 76.1)59.4 (42.3 to 74.5)
Unsolicited AE: 50-65 Years69.7 (52.7 to 82.6)61.8 (45.0 to 76.1)84.2 (62.4 to 94.5)
SecondaryGMTs for IgG Against Each OspA Serotype (ST1 to ST6): Booster Per-protocol (PP) Population

GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24, and Month 30. The outcome measure was planned to be analyzed for Booster PP population from Day 1 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.

Time frame:
At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30
Reported as:
Geometric mean · Units per milliliter (U/mL)
GMTs for IgG Against Each OspA Serotype (ST1 to ST6): Booster Per-protocol (PP) Population
Units per milliliter (U/mL)Booster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
ST1 Day 120.5 (19.5 to 21.4)20.0 (20.0 to 20.0)
ST1 Day 2920.9 (19.6 to 22.3)20.0 (20.0 to 20.0)
ST1 Day 5722.6 (19.8 to 25.8)20.0 (20.0 to 20.0)
ST1 Day 8578.9 (53.2 to 117.1)67.2 (41.2 to 109.6)
ST1 Day 18027.6 (23.4 to 32.5)24.2 (19.4 to 30.3)
ST1 Day 208292.0 (198.1 to 430.3)349.5 (184.4 to 662.4)
ST1 Day 36539.7 (30.0 to 52.4)37.3 (20.9 to 66.4)
ST1 Day 54524.9 (21.2 to 29.2)24.0 (17.9 to 32.3)
ST1 Month 191277.0 (861.8 to 1892.3)23.6 (18.1 to 30.8)
ST1 Month 24137.4 (95.8 to 196.9)22.3 (17.7 to 28.0)
ST1 Month 3054.1 (38.6 to 75.7)22.1 (17.9 to 27.4)
ST2 Day 120.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST2 Day 2923.4 (20.0 to 27.2)20.0 (20.0 to 20.0)
ST2 Day 5723.2 (19.3 to 27.8)20.0 (20.0 to 20.0)
ST2 Day 85219.3 (156.5 to 307.4)187.4 (109.2 to 321.8)
ST2 Day 18041.0 (31.1 to 54.1)33.5 (22.9 to 48.8)
ST2 Day 208606.3 (419.0 to 877.3)694.7 (427.9 to 1127.9)
ST2 Day 36576.1 (55.0 to 105.5)75.5 (44.0 to 129.6)
ST2 Day 54531.8 (25.2 to 40.1)35.9 (25.2 to 51.2)
ST2 Month 192194.5 (1566.8 to 3073.7)36.8 (26.4 to 51.3)
ST2 Month 24258.6 (197.4 to 338.8)26.0 (19.9 to 34.1)
ST2 Month 3089.5 (63.4 to 126.2)21.9 (18.0 to 26.6)
ST3 Day 120.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST3 Day 2920.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST3 Day 5721.8 (18.3 to 25.9)20.0 (20.0 to 20.0)
ST3 Day 85235.1 (155.9 to 354.3)237.6 (152.4 to 370.4)
ST3 Day 18047.6 (36.7 to 61.7)43.9 (28.0 to 68.8)
ST3 Day 208631.9 (431.2 to 925.9)666.3 (393.9 to 1127.3)
ST3 Day 36578.7 (57.2 to 108.3)81.1 (44.0 to 149.7)
ST3 Day 54531.1 (24.8 to 38.8)39.5 (25.9 to 60.4)
ST3 Month 191916.2 (1320.7 to 2780.2)35.8 (24.9 to 51.7)
ST3 Month 24265.8 (202.9 to 348.2)29.1 (20.8 to 40.6)
ST3 Month 30101.6 (77.6 to 133.1)24.9 (19.0 to 32.6)
ST4 Day 120.8 (19.2 to 22.4)20.0 (20.0 to 20.0)
ST4 Day 2921.2 (19.5 to 23.1)20.0 (20.0 to 20.0)
ST4 Day 5722.2 (19.6 to 25.1)20.0 (20.0 to 20.0)
ST4 Day 85108.9 (75.9 to 156.3)100.7 (65.1 to 155.6)
ST4 Day 18030.1 (24.7 to 36.6)28.4 (21.2 to 38.2)
ST4 Day 208376.6 (261.1 to 543.3)455.3 (268.2 to 773.1)
ST4 Day 36547.5 (35.8 to 62.9)46.5 (26.7 to 80.9)
ST4 Day 54528.8 (23.8 to 34.8)31.3 (22.5 to 43.7)
ST4 Month 191661.1 (1156.4 to 2386.0)26.5 (19.9 to 35.4)
ST4 Month 24200.7 (150.9 to 266.8)24.6 (18.9 to 32.0)
ST4 Month 3072.3 (52.2 to 100.1)22.1 (17.9 to 27.3)
ST5 Day 120.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST5 Day 2922.1 (19.5 to 25.0)20.0 (20.0 to 20.0)
ST5 Day 5723.3 (19.7 to 27.5)20.0 (20.0 to 20.0)
ST5 Day 85100.9 (70.6 to 144.1)127.4 (85.5 to 189.8)
ST5 Day 18026.5 (22.3 to 31.6)32.3 (23.4 to 44.7)
ST5 Day 208370.6 (257.3 to 533.8)528.4 (330.8 to 844.0)
ST5 Day 36543.9 (32.5 to 59.3)59.4 (35.9 to 98.4)
ST5 Day 54525.0 (21.1 to 29.7)31.1 (22.0 to 44.0)
ST5 Month 191507.9 (1066.0 to 2133.0)25.5 (19.2 to 33.8)
ST5 Month 24170.2 (127.2 to 227.7)23.7 (18.5 to 30.3)
ST5 Month 3074.0 (54.9 to 99.7)23.6 (18.6 to 29.9)
ST6 Day 120.9 (19.2 to 22.7)20.0 (20.0 to 20.0)
ST6 Day 2922.0 (19.6 to 24.7)20.0 (20.0 to 20.0)
ST6 Day 5724.8 (20.7 to 29.9)20.0 (20.0 to 20.0)
ST6 Day 8582.0 (57.3 to 117.3)116.5 (74.3 to 182.5)
ST6 Day 18029.2 (23.8 to 35.7)36.4 (25.4 to 52.2)
ST6 Day 208351.9 (246.7 to 502.0)509.0 (308.6 to 839.4)
ST6 Day 36546.8 (33.7 to 65.0)67.3 (41.6 to 108.7)
ST6 Day 54526.3 (21.6 to 32.0)29.1 (21.0 to 40.4)
ST6 Month 191406.8 (996.2 to 1986.7)28.7 (21.1 to 39.2)
ST6 Month 24181.5 (138.9 to 237.1)25.8 (19.9 to 33.5)
ST6 Month 3076.0 (55.7 to 103.8)23.8 (18.4 to 30.6)
SecondarySCRs for Each OspA Serotype Specific IgG (ST1 to ST6): Booster PP Population

SCR for each OspA serotype specific IgG ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24, and Month 30. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): greater than or equal to (\>=) 4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants. Percentages are based on the number of participants with non-missing observations. The outcome measure was planned to be analyzed for Booster PP population from Day 29 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.

Time frame:
Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30
Reported as:
Number · Percentage of Participants
SCRs for Each OspA Serotype Specific IgG (ST1 to ST6): Booster PP Population
Percentage of ParticipantsBooster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
ST1 Day 292.7 (0.5 to 13.8)0.0 (0.0 to 17.6)
ST1 Day 578.1 (2.8 to 21.3)0.0 (0.0 to 17.6)
ST1 Day 8564.9 (48.8 to 78.2)70.6 (46.9 to 86.7)
ST1 Day 18029.7 (17.5 to 45.8)16.7 (5.8 to 39.2)
ST1 Day 20897.1 (85.5 to 99.5)100 (81.6 to 100)
ST1 Day 36543.2 (28.7 to 59.1)29.4 (13.3 to 53.1)
ST1 Day 54516.2 (7.7 to 31.1)11.1 (3.1 to 32.8)
ST1 Month 19100 (90.6 to 100)11.1 (3.1 to 32.8)
ST1 Month 2489.2 (75.3 to 95.7)5.9 (1.0 to 27.0)
ST1 Month 3056.8 (40.9 to 71.3)5.9 (1.0 to 27.0)
ST2 Day 2910.8 (4.3 to 24.7)0.0 (0.0 to 17.6)
ST2 Day 578.1 (2.8 to 21.3)0.0 (0.0 to 17.6)
ST2 Day 8597.3 (86.2 to 99.5)88.2 (65.7 to 96.7)
ST2 Day 18048.6 (33.4 to 64.1)33.3 (16.3 to 56.3)
ST2 Day 20897.1 (85.5 to 99.5)100 (81.6 to 100)
ST2 Day 36575.7 (59.9 to 86.6)70.6 (46.9 to 86.7)
ST2 Day 54535.1 (21.8 to 51.2)44.4 (24.6 to 66.3)
ST2 Month 19100 (90.6 to 100)50.0 (29.0 to 71.0)
ST2 Month 24100 (90.6 to 100)23.5 (9.6 to 47.3)
ST2 Month 3073.0 (57.0 to 84.6)5.9 (1.0 to 27.0)
ST3 Day 290.0 (0.0 to 9.4)0.0 (0.0 to 17.6)
ST3 Day 572.7 (0.5 to 13.8)0.0 (0.0 to 17.6)
ST3 Day 8589.2 (75.3 to 95.7)100 (81.6 to 100)
ST3 Day 18059.5 (43.5 to 73.7)50.0 (29.0 to 71.0)
ST3 Day 20897.1 (85.5 to 99.5)100 (81.6 to 100)
ST3 Day 36573.0 (57.0 to 84.6)70.6 (46.9 to 86.7)
ST3 Day 54532.4 (19.6 to 48.5)44.4 (24.6 to 66.3)
ST3 Month 19100 (90.6 to 100)44.4 (24.6 to 66.3)
ST3 Month 24100 (90.6 to 100)29.4 (13.3 to 53.1)
ST3 Month 3089.2 (75.3 to 95.7)17.6 (6.2 to 41.0)
ST4 Day 292.7 (0.5 to 13.8)0.0 (0.0 to 17.6)
ST4 Day 575.4 (1.5 to 17.7)0.0 (0.0 to 17.6)
ST4 Day 8581.1 (65.8 to 90.5)88.2 (65.7 to 96.7)
ST4 Day 18032.4 (19.6 to 48.5)27.8 (12.5 to 50.9)
ST4 Day 20897.1 (85.5 to 99.5)100 (81.6 to 100)
ST4 Day 36556.8 (40.9 to 71.3)52.9 (31.0 to 73.8)
ST4 Day 54529.7 (17.5 to 45.8)38.9 (20.3 to 61.4)
ST4 Month 19100 (90.6 to 100)22.2 (9.0 to 45.2)
ST4 Month 24100 (90.6 to 100)17.6 (6.2 to 41.0)
ST4 Month 3073.0 (57.0 to 84.6)5.9 (1.0 to 27.0)
ST5 Day 298.1 (2.8 to 21.3)0.0 (0.0 to 17.6)
ST5 Day 5710.8 (4.3 to 24.7)0.0 (0.0 to 17.6)
ST5 Day 8578.4 (62.8 to 88.6)94.1 (73.0 to 99.0)
ST5 Day 18024.3 (13.4 to 40.1)38.9 (20.3 to 61.4)
ST5 Day 20897.1 (85.5 to 99.5)100 (81.6 to 100)
ST5 Day 36548.6 (33.4 to 64.1)70.6 (46.9 to 86.7)
ST5 Day 54518.9 (9.5 to 34.2)33.3 (16.3 to 56.3)
ST5 Month 19100 (90.6 to 100)16.7 (5.8 to 39.2)
ST5 Month 2497.3 (86.2 to 99.5)11.8 (3.3 to 34.3)
ST5 Month 3081.1 (65.8 to 90.5)11.8 (3.3 to 34.3)
ST6 Day 295.4 (1.5 to 17.7)0.0 (0.0 to 17.6)
ST6 Day 5713.5 (5.9 to 28.0)0.0 (0.0 to 17.6)
ST6 Day 8570.3 (54.2 to 82.5)88.2 (65.7 to 96.7)
ST6 Day 18027.0 (15.4 to 43.0)44.4 (24.6 to 66.3)
ST6 Day 20897.1 (85.5 to 99.5)100 (81.6 to 100)
ST6 Day 36545.9 (31.0 to 61.6)76.5 (52.7 to 90.4)
ST6 Day 54516.2 (7.7 to 31.1)27.8 (12.5 to 50.9)
ST6 Month 19100 (90.6 to 100)27.8 (12.5 to 50.9)
ST6 Month 2497.3 (86.2 to 99.5)23.5 (9.6 to 47.3)
ST6 Month 3073.0 (57.0 to 84.6)11.8 (3.3 to 34.3)
SecondaryGMFR as Compared to Baseline for IgG Against Each OspA Serotype (ST1 to ST6): Booster PP Population

GMFR as compared to baseline for IgG against each Osp serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24 and Month 30 were reported in this outcome measure. The outcome measure was planned to be analyzed for Booster PP population from Day 1 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.

Time frame:
Day 1 (baseline from where comparison was done), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30
Reported as:
Geometric mean · Fold Rise
GMFR as Compared to Baseline for IgG Against Each OspA Serotype (ST1 to ST6): Booster PP Population
Fold RiseBooster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
ST1 Day 291.0 (1.0 to 1.1)1.0 (1.0 to 1.0)
ST1 Day 571.1 (1.0 to 1.3)1.0 (1.0 to 1.0)
ST1 Day 853.9 (2.6 to 5.7)3.4 (2.1 to 5.5)
ST1 Day 1801.3 (1.2 to 1.6)1.2 (1.0 to 1.5)
ST1 Day 20814.2 (9.7 to 21.0)17.5 (9.2 to 33.1)
ST1 Day 3651.9 (1.5 to 2.6)1.9 (1.0 to 3.3)
ST1 Day 5451.2 (1.0 to 1.4)1.2 (0.9 to 1.6)
ST1 Month 1962.4 (42.6 to 91.4)1.2 (0.9 to 1.5)
ST1 Month 246.7 (4.7 to 9.6)1.1 (0.9 to 1.4)
ST1 Month 302.6 (1.9 to 3.7)1.1 (0.9 to 1.4)
ST2 Day 291.2 (1.0 to 1.4)1.0 (1.0 to 1.0)
ST2 Day 571.2 (1.0 to 1.4)1.0 (1.0 to 1.0)
ST2 Day 8511.0 (7.8 to 15.4)9.4 (5.5 to 16.1)
ST2 Day 1802.1 (1.6 to 2.7)1.7 (1.1 to 2.4)
ST2 Day 20830.3 (21.0 to 43.9)34.7 (21.4 to 56.4)
ST2 Day 3653.8 (2.7 to 5.3)3.8 (2.2 to 6.5)
ST2 Day 5451.6 (1.3 to 2.0)1.8 (1.3 to 2.6)
ST2 Month 19109.7 (78.3 to 153.7)1.8 (1.3 to 2.6)
ST2 Month 2412.9 (9.9 to 16.9)1.3 (1.0 to 1.7)
ST2 Month 304.5 (3.2 to 6.3)1.1 (0.9 to 1.3)
ST3 Day 291.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
ST3 Day 571.1 (0.9 to 1.3)1.0 (1.0 to 1.0)
ST3 Day 8511.8 (7.8 to 17.7)11.9 (7.6 to 18.5)
ST3 Day 1802.4 (1.8 to 3.1)2.2 (1.4 to 3.4)
ST3 Day 20831.6 (21.6 to 46.3)33.3 (19.7 to 56.4)
ST3 Day 3653.9 (2.9 to 5.4)4.1 (2.2 to 7.5)
ST3 Day 5451.6 (1.2 to 1.9)2.0 (1.3 to 3.0)
ST3 Month 1995.8 (66.0 to 139.0)1.8 (1.2 to 2.6)
ST3 Month 2413.3 (10.1 to 17.4)1.5 (1.0 to 2.0)
ST3 Month 305.1 (3.9 to 6.7)1.2 (0.9 to 1.6)
ST4 Day 291.0 (1.0 to 1.1)1.0 (1.0 to 1.0)
ST4 Day 571.1 (1.0 to 1.2)1.0 (1.0 to 1.0)
ST4 Day 855.2 (3.7 to 7.4)5.0 (3.3 to 7.8)
ST4 Day 1801.4 (1.2 to 1.7)1.4 (1.1 to 1.9)
ST4 Day 20818.1 (12.6 to 25.9)22.8 (13.4 to 38.7)
ST4 Day 3652.3 (1.7 to 3.0)2.3 (1.3 to 4.0)
ST4 Day 5451.4 (1.2 to 1.6)1.6 (1.1 to 2.2)
ST4 Month 1979.9 (56.5 to 113.1)1.3 (1.0 to 1.8)
ST4 Month 249.7 (7.3 to 12.8)1.2 (0.9 to 1.6)
ST4 Month 303.5 (2.5 to 4.8)1.1 (0.9 to 1.4)
ST5 Day 291.1 (1.0 to 1.2)1.0 (1.0 to 1.0)
ST5 Day 571.2 (1.0 to 1.4)1.0 (1.0 to 1.0)
ST5 Day 855.0 (3.5 to 7.2)6.4 (4.3 to 9.5)
ST5 Day 1801.3 (1.1 to 1.6)1.6 (1.2 to 2.2)
ST5 Day 20818.5 (12.9 to 26.7)26.4 (16.5 to 42.2)
ST5 Day 3652.2 (1.6 to 3.0)3.0 (1.8 to 4.9)
ST5 Day 5451.3 (1.1 to 1.5)1.6 (1.1 to 2.2)
ST5 Month 1975.4 (53.3 to 106.7)1.3 (1.0 to 1.7)
ST5 Month 248.5 (6.4 to 11.4)1.2 (0.9 to 1.5)
ST5 Month 303.7 (2.7 to 5.0)1.2 (0.9 to 1.5)
ST6 Day 291.1 (1.0 to 1.1)1.0 (1.0 to 1.0)
ST6 Day 571.2 (1.0 to 1.4)1.0 (1.0 to 1.0)
ST6 Day 853.9 (2.8 to 5.6)5.8 (3.7 to 9.1)
ST6 Day 1801.4 (1.2 to 1.7)1.8 (1.3 to 2.6)
ST6 Day 20816.8 (11.8 to 24.0)25.4 (15.4 to 42.0)
ST6 Day 3652.2 (1.6 to 3.1)3.4 (2.1 to 5.4)
ST6 Day 5451.3 (1.1 to 1.5)1.5 (1.1 to 2.0)
ST6 Month 1967.5 (48.4 to 94.0)1.4 (1.1 to 2.0)
ST6 Month 248.7 (6.7 to 11.4)1.3 (1.0 to 1.7)
ST6 Month 303.6 (2.7 to 4.9)1.2 (0.9 to 1.5)
SecondaryGMFR as Compared to Day 208 for IgG Against Each OspA Serotype (ST1 to ST6): Booster PP Population

GMFR as compared to Day 208 for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Month 19, Month 24 and Month 30. The outcome measure was planned to be analyzed for Booster PP population from Day 208 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.

Time frame:
Day 208 (from where comparison was done), Month 19, Month 24 and Month 30
Reported as:
Geometric mean · Fold Rise
GMFR as Compared to Day 208 for IgG Against Each OspA Serotype (ST1 to ST6): Booster PP Population
Fold RiseBooster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
ST1 Month 194.2 (3.4 to 5.2)0.1 (0.0 to 0.1)
ST1 Month 240.5 (0.4 to 0.6)0.1 (0.0 to 0.1)
ST1 Month 300.2 (0.1 to 0.2)0.1 (0.0 to 0.1)
ST2 Month 193.5 (2.9 to 4.3)0.1 (0.0 to 0.1)
ST2 Month 240.4 (0.3 to 0.5)0.0 (0.0 to 0.1)
ST2 Month 300.1 (0.1 to 0.2)0.0 (0.0 to 0.0)
ST3 Month 192.9 (2.3 to 3.5)0.1 (0.0 to 0.1)
ST3 Month 240.4 (0.3 to 0.5)0.0 (0.0 to 0.1)
ST3 Month 300.2 (0.1 to 0.2)0.0 (0.0 to 0.1)
ST4 Month 194.2 (3.5 to 5.1)0.1 (0.0 to 0.1)
ST4 Month 240.5 (0.4 to 0.7)0.1 (0.0 to 0.1)
ST4 Month 300.2 (0.1 to 0.3)0.0 (0.0 to 0.1)
ST5 Month 194.0 (3.3 to 4.8)0.0 (0.0 to 0.1)
ST5 Month 240.5 (0.4 to 0.6)0.0 (0.0 to 0.1)
ST5 Month 300.2 (0.1 to 0.3)0.0 (0.0 to 0.1)
ST6 Month 193.9 (3.2 to 4.7)0.1 (0.0 to 0.1)
ST6 Month 240.5 (0.4 to 0.7)0.1 (0.0 to 0.1)
ST6 Month 300.2 (0.2 to 0.3)0.0 (0.0 to 0.1)
SecondaryGMFR as Compared to Month 18 (Pre-booster) for IgG Against Each OspA Serotype (ST1 to ST6): Booster PP Population

GMFR as compared to Month 18 (pre-booster) for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Month 19, Month 24 and Month 30. The outcome measure was planned to be analyzed for Booster PP population.

Time frame:
Month 18 (from where comparison was done), Month 19, Month 24 and Month 30
Reported as:
Geometric mean · Fold Rise
GMFR as Compared to Month 18 (Pre-booster) for IgG Against Each OspA Serotype (ST1 to ST6): Booster PP Population
Fold RiseBooster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
ST1 Month 1951.3 (37.1 to 71.0)1.0 (1.0 to 1.0)
ST1 Month 245.5 (4.2 to 7.3)0.9 (0.8 to 1.0)
ST1 Month 302.2 (1.7 to 2.8)0.9 (0.8 to 1.0)
ST2 Month 1969.1 (54.2 to 88.0)1.0 (0.9 to 1.2)
ST2 Month 248.1 (6.8 to 9.8)0.8 (0.6 to 0.9)
ST2 Month 302.8 (2.2 to 3.6)0.6 (0.5 to 0.9)
ST3 Month 1961.7 (46.2 to 82.5)0.9 (0.8 to 1.0)
ST3 Month 248.6 (7.0 to 10.4)0.8 (0.6 to 1.0)
ST3 Month 303.3 (2.6 to 4.0)0.7 (0.5 to 0.9)
ST4 Month 1957.7 (42.4 to 78.6)0.8 (0.7 to 1.0)
ST4 Month 247.0 (5.6 to 8.7)0.8 (0.7 to 1.0)
ST4 Month 302.5 (2.0 to 3.2)0.7 (0.6 to 0.9)
ST5 Month 1960.2 (45.1 to 80.4)0.8 (0.7 to 1.0)
ST5 Month 246.8 (5.4 to 8.6)0.8 (0.7 to 1.0)
ST5 Month 303.0 (2.3 to 3.8)0.8 (0.7 to 1.0)
ST6 Month 1953.5 (39.2 to 73.2)1.0 (0.8 to 1.2)
ST6 Month 246.9 (5.4 to 8.9)0.9 (0.9 to 1.0)
ST6 Month 302.9 (2.2 to 3.8)0.9 (0.7 to 1.0)
SecondaryGMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 18 - 49 Years

GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24 and Month 30 stratified by age group: 18 - 49 years. The outcome measure was planned to be analyzed for Booster PP population from Day 1 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.

Time frame:
At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30
Reported as:
Geometric mean · Units per milliliter (U/mL)
GMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 18 - 49 Years
Units per milliliter (U/mL)Booster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
ST1 Day 120.8 (19.2 to 22.5)20.0 (20.0 to 20.0)
ST1 Day 2921.6 (19.3 to 24.1)20.0 (20.0 to 20.0)
ST1 Day 5722.5 (19.7 to 25.8)20.0 (20.0 to 20.0)
ST1 Day 85103.1 (60.3 to 176.4)62.8 (33.6 to 117.4)
ST1 Day 18029.2 (23.0 to 37.0)21.9 (18.0 to 26.7)
ST1 Day 208335.9 (199.7 to 565.0)335.3 (189.4 to 593.7)
ST1 Day 36539.3 (27.5 to 56.4)34.8 (20.6 to 58.7)
ST1 Day 54524.6 (20.0 to 30.2)21.4 (18.4 to 24.9)
ST1 Month 191551.7 (943.9 to 2550.8)21.4 (18.5 to 24.8)
ST1 Month 24142.1 (90.9 to 222.1)20.0 (20.0 to 20.0)
ST1 Month 3056.4 (37.6 to 84.8)20.0 (20.0 to 20.0)
ST2 Day 120.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST2 Day 2924.7 (19.3 to 31.7)20.0 (20.0 to 20.0)
ST2 Day 5725.7 (18.9 to 35.0)20.0 (20.0 to 20.0)
ST2 Day 85252.1 (160.9 to 395.1)213.1 (110.0 to 412.8)
ST2 Day 18043.0 (29.5 to 62.6)36.4 (22.4 to 59.3)
ST2 Day 208608.9 (428.2 to 866.0)761.7 (531.8 to 1091.0)
ST2 Day 36565.0 (44.5 to 94.8)88.8 (53.3 to 148.1)
ST2 Day 54528.9 (22.6 to 37.0)38.3 (26.0 to 56.5)
ST2 Month 192199.0 (1423.5 to 3396.9)40.2 (28.0 to 57.7)
ST2 Month 24230.4 (166.9 to 317.9)25.1 (19.3 to 32.7)
ST2 Month 3072.8 (45.9 to 115.3)20.0 (20.0 to 20.0)
ST3 Day 120.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST3 Day 2920.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST3 Day 5723.1 (17.1 to 31.1)20.0 (20.0 to 20.0)
ST3 Day 85280.1 (162.1 to 483.9)266.8 (154.9 to 459.4)
ST3 Day 18052.8 (37.8 to 73.9)45.9 (26.6 to 79.4)
ST3 Day 208710.0 (476.3 to 1058.3)696.6 (449.8 to 1078.7)
ST3 Day 36578.1 (53.2 to 114.6)91.0 (50.6 to 163.7)
ST3 Day 54530.4 (22.7 to 40.7)41.5 (27.0 to 63.7)
ST3 Month 191997.3 (1280.0 to 3116.6)37.5 (25.6 to 55.0)
ST3 Month 24246.0 (174.9 to 346.2)28.3 (20.3 to 39.5)
ST3 Month 3096.3 (68.9 to 134.8)23.3 (18.5 to 29.2)
ST4 Day 121.3 (18.7 to 24.4)20.0 (20.0 to 20.0)
ST4 Day 2922.0 (19.1 to 25.5)20.0 (20.0 to 20.0)
ST4 Day 5723.8 (19.3 to 29.4)20.0 (20.0 to 20.0)
ST4 Day 85134.8 (82.5 to 220.4)105.4 (61.4 to 180.8)
ST4 Day 18031.1 (23.5 to 41.1)29.5 (20.3 to 43.0)
ST4 Day 208432.0 (288.2 to 647.4)458.6 (306.9 to 685.3)
ST4 Day 36545.8 (31.9 to 65.8)47.3 (29.9 to 74.9)
ST4 Day 54529.3 (22.8 to 37.5)28.6 (21.4 to 38.2)
ST4 Month 191817.7 (1179.3 to 2801.5)25.4 (19.3 to 33.4)
ST4 Month 24191.7 (138.8 to 264.8)22.8 (18.7 to 27.8)
ST4 Month 3066.8 (44.8 to 99.5)20.0 (20.0 to 20.0)
ST5 Day 120.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST5 Day 2921.0 (19.0 to 23.1)20.0 (20.0 to 20.0)
ST5 Day 5723.6 (18.1 to 30.6)20.0 (20.0 to 20.0)
ST5 Day 85120.6 (74.6 to 195.0)122.6 (70.7 to 212.7)
ST5 Day 18027.4 (21.5 to 34.9)31.9 (21.4 to 47.4)
ST5 Day 208380.7 (238.8 to 607.1)506.8 (323.4 to 794.1)
ST5 Day 36542.5 (29.7 to 60.9)55.0 (32.7 to 92.6)
ST5 Day 54525.1 (20.5 to 30.7)31.6 (21.5 to 46.5)
ST5 Month 191600.5 (1002.8 to 2554.6)24.4 (18.1 to 32.8)
ST5 Month 24160.2 (109.5 to 234.3)22.2 (17.6 to 27.9)
ST5 Month 3078.1 (57.1 to 106.7)22.3 (17.6 to 28.1)
ST6 Day 121.5 (18.5 to 24.8)20.0 (20.0 to 20.0)
ST6 Day 2922.7 (18.9 to 27.3)20.0 (20.0 to 20.0)
ST6 Day 5727.3 (20.4 to 36.5)20.0 (20.0 to 20.0)
ST6 Day 8590.2 (53.9 to 151.0)121.4 (72.1 to 204.5)
ST6 Day 18028.5 (21.7 to 37.5)34.4 (21.8 to 54.1)
ST6 Day 208346.1 (217.3 to 551.1)502.5 (314.1 to 803.8)
ST6 Day 36542.8 (28.7 to 63.8)63.1 (38.1 to 104.4)
ST6 Day 54525.4 (20.0 to 32.4)28.7 (20.3 to 40.6)
ST6 Month 191449.3 (878.4 to 2391.3)28.7 (20.3 to 40.6)
ST6 Month 24163.8 (115.0 to 233.2)25.1 (19.1 to 32.8)
ST6 Month 3069.6 (48.1 to 100.7)22.1 (17.7 to 27.7)
SecondaryGMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 50 - 65 Years

GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24 and Month 30 stratified by age group: 50 - 65 years. The outcome measure was planned to be analyzed for Booster PP population from Day 1 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.

Time frame:
At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30
Reported as:
Geometric mean · Units per milliliter (U/mL)
GMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 50 - 65 Years
Units per milliliter (U/mL)Booster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
ST1 Day 120.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST1 Day 2920.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST1 Day 5722.8 (17.2 to 30.3)20.0 (20.0 to 20.0)
ST1 Day 8553.3 (29.6 to 95.9)78.8 (24.0 to 259.4)
ST1 Day 18025.4 (20.2 to 31.9)31.6 (14.3 to 69.6)
ST1 Day 208236.6 (124.2 to 450.7)386.0 (32.8 to 4546.3)
ST1 Day 36540.2 (24.4 to 66.0)44.1 (4.9 to 396.6)
ST1 Day 54525.3 (19.0 to 33.8)32.3 (8.5 to 122.8)
ST1 Month 19959.7 (482.2 to 1910.2)30.7 (9.4 to 100.7)
ST1 Month 24130.8 (66.8 to 256.0)28.8 (10.5 to 79.3)
ST1 Month 3050.8 (26.7 to 96.6)28.2 (10.8 to 73.5)
ST2 Day 120.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST2 Day 2921.4 (18.5 to 24.9)20.0 (20.0 to 20.0)
ST2 Day 5720.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST2 Day 85178.8 (102.1 to 313.1)137.8 (33.9 to 559.6)
ST2 Day 18038.3 (24.2 to 60.5)26.8 (11.9 to 60.2)
ST2 Day 208602.4 (260.7 to 1391.7)557.0 (75.6 to 4104.2)
ST2 Day 36596.1 (51.6 to 179.2)51.1 (7.6 to 344.7)
ST2 Day 54536.5 (22.5 to 59.2)30.4 (9.5 to 96.6)
ST2 Month 192187.9 (1198.0 to 3995.8)29.3 (10.2 to 84.1)
ST2 Month 24306.4 (184.2 to 509.5)28.4 (10.7 to 75.4)
ST2 Month 30121.2 (70.6 to 207.9)27.3 (11.5 to 64.9)
ST3 Day 120.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST3 Day 2920.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST3 Day 5720.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST3 Day 85181.8 (92.4 to 357.8)179.8 (57.8 to 559.6)
ST3 Day 18040.8 (26.0 to 64.1)39.0 (11.4 to 133.7)
ST3 Day 208530.4 (234.5 to 1199.8)599.0 (73.4 to 4891.0)
ST3 Day 36579.7 (43.1 to 147.3)61.6 (6.7 to 566.4)
ST3 Day 54532.1 (21.6 to 47.6)34.9 (7.4 to 163.5)
ST3 Month 191803.1 (878.3 to 3701.5)31.8 (8.8 to 115.6)
ST3 Month 24297.8 (183.0 to 484.6)30.9 (9.3 to 102.9)
ST3 Month 30109.9 (66.6 to 181.3)29.2 (10.2 to 83.7)
ST4 Day 120.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST4 Day 2920.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST4 Day 5720.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST4 Day 8579.7 (45.8 to 138.7)90.2 (28.5 to 285.4)
ST4 Day 18028.6 (21.4 to 38.4)25.8 (12.8 to 52.1)
ST4 Day 208306.6 (144.9 to 648.8)447.5 (49.6 to 4039.3)
ST4 Day 36550.0 (30.2 to 82.7)44.5 (4.8 to 411.4)
ST4 Day 54528.1 (20.1 to 39.2)39.7 (10.8 to 146.7)
ST4 Month 191455.5 (726.5 to 2916.0)29.8 (9.9 to 89.8)
ST4 Month 24214.6 (121.0 to 380.7)29.3 (10.2 to 84.1)
ST4 Month 3081.2 (44.1 to 149.3)28.1 (10.9 to 72.0)
ST5 Day 120.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST5 Day 2923.8 (17.9 to 31.8)20.0 (20.0 to 20.0)
ST5 Day 5722.8 (18.7 to 27.8)20.0 (20.0 to 20.0)
ST5 Day 8577.7 (44.0 to 137.0)139.8 (69.1 to 282.8)
ST5 Day 18025.4 (19.2 to 33.6)33.5 (13.8 to 81.4)
ST5 Day 208356.0 (182.9 to 693.0)584.1 (104.2 to 3275.4)
ST5 Day 36545.9 (25.7 to 82.1)71.6 (12.7 to 403.9)
ST5 Day 54524.9 (17.8 to 34.9)30.0 (9.8 to 92.1)
ST5 Month 191381.6 (772.7 to 2470.1)28.5 (10.7 to 75.9)
ST5 Month 24186.0 (111.8 to 309.2)27.6 (11.3 to 67.4)
ST5 Month 3068.3 (36.3 to 128.6)27.0 (11.7 to 62.3)
ST6 Day 120.0 (20.0 to 20.0)20.0 (20.0 to 20.0)
ST6 Day 2921.1 (18.8 to 23.6)20.0 (20.0 to 20.0)
ST6 Day 5721.7 (18.3 to 25.7)20.0 (20.0 to 20.0)
ST6 Day 8571.4 (42.1 to 120.9)105.4 (27.3 to 407.4)
ST6 Day 18030.1 (21.4 to 42.4)42.2 (17.5 to 102.0)
ST6 Day 208360.9 (192.4 to 676.9)525.1 (80.5 to 3426.2)
ST6 Day 36553.4 (28.8 to 98.9)78.6 (15.5 to 398.1)
ST6 Day 54527.6 (19.0 to 40.0)30.2 (9.6 to 95.3)
ST6 Month 191346.7 (811.0 to 2236.3)28.8 (10.5 to 79.3)
ST6 Month 24210.9 (134.5 to 330.8)27.7 (11.2 to 68.5)
ST6 Month 3086.5 (47.6 to 157.4)28.1 (10.9 to 72.5)
SecondarySCR for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 18 - 49 Years

SCR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24 and Month 30 stratified by age group: 18 - 49 years was presented in this outcome measure. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): \>=4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants. The outcome measure was planned to be analyzed for Booster PP population from Day 29 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.

Time frame:
Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30
Reported as:
Number · Percentage of Participants
SCR for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 18 - 49 Years
Percentage of ParticipantsBooster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
ST1 Day 294.5 (0.8 to 21.8)0.0 (0.0 to 22.8)
ST1 Day 579.1 (2.5 to 27.8)0.0 (0.0 to 22.8)
ST1 Day 8572.7 (51.8 to 86.8)66.7 (39.1 to 86.2)
ST1 Day 18031.8 (16.4 to 52.7)7.7 (1.4 to 33.3)
ST1 Day 20895.2 (77.3 to 99.2)100 (75.8 to 100)
ST1 Day 36540.9 (23.3 to 61.3)33.3 (13.8 to 60.9)
ST1 Day 54513.6 (4.7 to 33.3)7.7 (1.4 to 33.3)
ST1 Month 19100 (85.1 to 100)7.7 (1.4 to 33.3)
ST1 Month 2490.9 (72.2 to 97.5)0.0 (0.0 to 24.2)
ST1 Month 3063.6 (43.0 to 80.3)0.0 (0.0 to 24.2)
ST2 Day 2913.6 (4.7 to 33.3)0.0 (0.0 to 22.8)
ST2 Day 5713.6 (4.7 to 33.3)0.0 (0.0 to 22.8)
ST2 Day 85100 (85.1 to 100)91.7 (64.6 to 98.5)
ST2 Day 18050.0 (30.7 to 69.3)38.5 (17.7 to 64.5)
ST2 Day 208100 (84.5 to 100)100 (75.8 to 100)
ST2 Day 36572.7 (51.8 to 86.8)83.3 (55.2 to 95.3)
ST2 Day 54531.8 (16.4 to 52.7)53.8 (29.1 to 76.8)
ST2 Month 19100 (85.1 to 100)61.5 (35.5 to 82.3)
ST2 Month 24100 (85.1 to 100)25.0 (8.9 to 53.2)
ST2 Month 3063.6 (43.0 to 80.3)0.0 (0.0 to 24.2)
ST3 Day 290.0 (0.0 to 14.9)0.0 (0.0 to 22.8)
ST3 Day 574.5 (0.8 to 21.8)0.0 (0.0 to 22.8)
ST3 Day 8590.9 (72.2 to 97.5)100 (75.8 to 100)
ST3 Day 18068.2 (47.3 to 83.6)53.8 (29.1 to 76.8)
ST3 Day 208100 (84.5 to 100)100 (75.8 to 100)
ST3 Day 36577.3 (56.6 to 89.9)83.3 (55.2 to 95.3)
ST3 Day 54531.8 (16.4 to 52.7)53.8 (29.1 to 76.8)
ST3 Month 19100 (85.1 to 100)53.8 (29.1 to 76.8)
ST3 Month 24100 (85.1 to 100)33.3 (13.8 to 60.9)
ST3 Month 3090.9 (72.2 to 97.5)16.7 (4.7 to 44.8)
ST4 Day 294.5 (0.8 to 21.8)0.0 (0.0 to 22.8)
ST4 Day 579.1 (2.5 to 27.8)0.0 (0.0 to 22.8)
ST4 Day 8586.4 (66.7 to 95.3)91.7 (64.6 to 98.5)
ST4 Day 18031.8 (16.4 to 52.7)30.8 (12.7 to 57.6)
ST4 Day 208100 (84.5 to 100)100 (75.8 to 100)
ST4 Day 36554.5 (34.7 to 73.1)66.7 (39.1 to 86.2)
ST4 Day 54531.8 (16.4 to 52.7)38.5 (17.7 to 64.5)
ST4 Month 19100 (85.1 to 100)23.1 (8.2 to 50.3)
ST4 Month 24100 (85.1 to 100)16.7 (4.7 to 44.8)
ST4 Month 3068.2 (47.3 to 83.6)0.0 (0.0 to 24.2)
ST5 Day 294.5 (0.8 to 21.8)0.0 (0.0 to 22.8)
ST5 Day 579.1 (2.5 to 27.8)0.0 (0.0 to 22.8)
ST5 Day 8581.8 (61.5 to 92.7)91.7 (64.6 to 98.5)
ST5 Day 18027.3 (13.2 to 48.2)38.5 (17.7 to 64.5)
ST5 Day 20895.2 (77.3 to 99.2)100 (75.8 to 100)
ST5 Day 36550.0 (30.7 to 69.3)66.7 (39.1 to 86.2)
ST5 Day 54522.7 (10.1 to 43.4)38.5 (17.7 to 64.5)
ST5 Month 19100 (85.1 to 100)15.4 (4.3 to 42.2)
ST5 Month 2495.5 (78.2 to 99.2)8.3 (1.5 to 35.4)
ST5 Month 3090.9 (72.2 to 97.5)8.3 (1.5 to 35.4)
ST6 Day 294.5 (0.8 to 21.8)0.0 (0.0 to 22.8)
ST6 Day 5718.2 (7.3 to 38.5)0.0 (0.0 to 22.8)
ST6 Day 8568.2 (47.3 to 83.6)91.7 (64.6 to 98.5)
ST6 Day 18022.7 (10.1 to 43.4)38.5 (17.7 to 64.5)
ST6 Day 20895.2 (77.3 to 99.2)100 (75.8 to 100)
ST6 Day 36540.9 (23.3 to 61.3)75.0 (46.8 to 91.1)
ST6 Day 54513.6 (4.7 to 33.3)30.8 (12.7 to 57.6)
ST6 Month 19100 (85.1 to 100)30.8 (12.7 to 57.6)
ST6 Month 2495.5 (78.2 to 99.2)25.0 (8.9 to 53.2)
ST6 Month 3072.7 (51.8 to 86.8)8.3 (1.5 to 35.4)
SecondarySCR for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 50 - 65 Years

SCR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24, and Month 30 stratified by age group: 50 - 65 years. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): \>=4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants. The outcome measure was planned to be analyzed for Booster PP population from Day 29 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.

Time frame:
Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30
Reported as:
Number · Percentage of Participants
SCR for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 50 - 65 Years
Percentage of ParticipantsBooster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
ST1 Day 290.0 (0.0 to 20.4)0.0 (0.0 to 43.4)
ST1 Day 576.7 (1.2 to 29.8)0.0 (0.0 to 43.4)
ST1 Day 8553.3 (30.1 to 75.2)80.0 (37.6 to 96.4)
ST1 Day 18026.7 (10.9 to 52.0)40.0 (11.8 to 76.9)
ST1 Day 208100 (78.5 to 100)100 (56.6 to 100)
ST1 Day 36546.7 (24.8 to 69.9)20.0 (3.6 to 62.4)
ST1 Day 54520.0 (7.0 to 45.2)20.0 (3.6 to 62.4)
ST1 Month 19100 (79.6 to 100)20.0 (3.6 to 62.4)
ST1 Month 2486.7 (62.1 to 96.3)20.0 (3.6 to 62.4)
ST1 Month 3046.7 (24.8 to 69.9)20.0 (3.6 to 62.4)
ST2 Day 296.7 (1.2 to 29.8)0.0 (0.0 to 43.4)
ST2 Day 570.0 (0.0 to 20.4)0.0 (0.0 to 43.4)
ST2 Day 8593.3 (70.2 to 98.8)80.0 (37.6 to 96.4)
ST2 Day 18046.7 (24.8 to 69.9)20.0 (3.6 to 62.4)
ST2 Day 20892.9 (68.5 to 98.7)100 (56.6 to 100)
ST2 Day 36580.0 (54.8 to 93.0)40.0 (11.8 to 76.9)
ST2 Day 54540.0 (19.8 to 64.3)20.0 (3.6 to 62.4)
ST2 Month 19100 (79.6 to 100)20.0 (3.6 to 62.4)
ST2 Month 24100 (79.6 to 100)20.0 (3.6 to 62.4)
ST2 Month 3086.7 (62.1 to 96.3)20.0 (3.6 to 62.4)
ST3 Day 290.0 (0.0 to 20.4)0.0 (0.0 to 43.4)
ST3 Day 570.0 (0.0 to 20.4)0.0 (0.0 to 43.4)
ST3 Day 8586.7 (62.1 to 96.3)100 (56.6 to 100)
ST3 Day 18046.7 (24.8 to 69.9)40.0 (11.8 to 76.9)
ST3 Day 20892.9 (68.5 to 98.7)100 (56.6 to 100)
ST3 Day 36566.7 (41.7 to 84.8)40.0 (11.8 to 76.9)
ST3 Day 54533.3 (15.2 to 58.3)20.0 (3.6 to 62.4)
ST3 Month 19100 (79.6 to 100)20.0 (3.6 to 62.4)
ST3 Month 24100 (79.6 to 100)20.0 (3.6 to 62.4)
ST3 Month 3086.7 (62.1 to 96.3)20.0 (3.6 to 62.4)
ST4 Day 290.0 (0.0 to 20.4)0.0 (0.0 to 43.4)
ST4 Day 570.0 (0.0 to 20.4)0.0 (0.0 to 43.4)
ST4 Day 8573.3 (48.0 to 89.1)80.0 (37.6 to 96.4)
ST4 Day 18033.3 (15.2 to 58.3)20.0 (3.6 to 62.4)
ST4 Day 20892.9 (68.5 to 98.7)100 (56.6 to 100)
ST4 Day 36560.0 (35.7 to 80.2)20.0 (3.6 to 62.4)
ST4 Day 54526.7 (10.9 to 52.0)40.0 (11.8 to 76.9)
ST4 Month 19100 (79.6 to 100)20.0 (3.6 to 62.4)
ST4 Month 24100 (79.6 to 100)20.0 (3.6 to 62.4)
ST4 Month 3080.0 (54.8 to 93.0)20.0 (3.6 to 62.4)
ST5 Day 2913.3 (3.7 to 37.9)0.0 (0.0 to 43.4)
ST5 Day 5713.3 (3.7 to 37.9)0.0 (0.0 to 43.4)
ST5 Day 8573.3 (48.0 to 89.1)100 (56.6 to 100)
ST5 Day 18020.0 (7.0 to 45.2)40.0 (11.8 to 76.9)
ST5 Day 208100 (78.5 to 100)100 (56.6 to 100)
ST5 Day 36546.7 (24.8 to 69.9)80.0 (37.6 to 96.4)
ST5 Day 54513.3 (3.7 to 37.9)20.0 (3.6 to 62.4)
ST5 Month 19100 (79.6 to 100)20.0 (3.6 to 62.4)
ST5 Month 24100 (79.6 to 100)20.0 (3.6 to 62.4)
ST5 Month 3066.7 (41.7 to 84.8)20.0 (3.6 to 62.4)
ST6 Day 296.7 (1.2 to 29.8)0.0 (0.0 to 43.4)
ST6 Day 576.7 (1.2 to 29.8)0.0 (0.0 to 43.4)
ST6 Day 8573.3 (48.0 to 89.1)80.0 (37.6 to 96.4)
ST6 Day 18033.3 (15.2 to 58.3)60.0 (23.1 to 88.2)
ST6 Day 208100 (78.5 to 100)100 (56.6 to 100)
ST6 Day 36553.3 (30.1 to 75.2)80.0 (37.6 to 96.4)
ST6 Day 54520.0 (7.0 to 45.2)20.0 (3.6 to 62.4)
ST6 Month 19100 (79.6 to 100)20.0 (3.6 to 62.4)
ST6 Month 24100 (79.6 to 100)20.0 (3.6 to 62.4)
ST6 Month 3073.3 (48.0 to 89.1)20.0 (3.6 to 62.4)
SecondaryPercentage of Participants With SAEs During the Entire Booster Phase

SAE was any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. Two-sided 95% confidence intervals were calculated according to Altman method.

Time frame:
From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With SAEs During the Entire Booster Phase
Percentage of ParticipantsBooster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
Percentage of Participants With SAEs During the Entire Booster Phase7.7 (2.7 to 20.3)0.0 (0.0 to 16.8)
SecondaryPercentage of Participants With Related SAEs During the Entire Booster Phase

SAE was any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.

Time frame:
From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Related SAEs During the Entire Booster Phase
Percentage of ParticipantsBooster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
Percentage of Participants With Related SAEs During the Entire Booster Phase0.0 (0.0 to 9.0)0.0 (0.0 to 16.8)
SecondaryPercentage of Participants With Adverse Event of Special Interest (AESIs) During the Entire Booster Phase

AESIs were defined as serious or non-serious AEs which were of scientific and medical concern specific to the investigational product. Two-sided 95% confidence intervals were calculated according to Altman method.

Time frame:
From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Event of Special Interest (AESIs) During the Entire Booster Phase
Percentage of ParticipantsBooster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
Percentage of Participants With Adverse Event of Special Interest (AESIs) During the Entire Booster Phase2.6 (0.5 to 13.2)0.0 (0.0 to 16.8)
SecondaryPercentage of Participants With Related AESIs During the Entire Booster Phase

AESIs were defined as serious or non-serious AEs which were of scientific and medical concern specific to the investigational product. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.

Time frame:
From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Related AESIs During the Entire Booster Phase
Percentage of ParticipantsBooster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
Percentage of Participants With Related AESIs During the Entire Booster Phase0.0 (0.0 to 9.0)0.0 (0.0 to 16.8)
SecondaryPercentage of Participants With Unsolicited AEs During the Booster Phase up to Month 19

An unsolicited AE includes any untoward medical occurrence in a clinical investigation participant temporally associated with the use of investigational product, whether or not related to investigational product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up (more than 6 days after vaccination) for solicited symptoms. Two-sided 95% confidence intervals were calculated according to Altman method.

Time frame:
From Day of vaccination in booster phase (Month 18) up to Month 19 (Approximately for 1 Month)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Unsolicited AEs During the Booster Phase up to Month 19
Percentage of ParticipantsBooster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
Percentage of Participants With Unsolicited AEs During the Booster Phase up to Month 1915.4 (7.2 to 29.7)5.3 (0.9 to 24.6)
SecondaryPercentage of Participants With Related Unsolicited AEs During the Booster Phase up to Month 19

An unsolicited AE included any untoward medical occurrence in a clinical investigation participant temporally associated with the use of investigational product, whether or not related to investigational product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up (more than 6 days after vaccination) for solicited symptoms. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.

Time frame:
From Day of vaccination in booster phase (Month 18) up to Month 19 (Approximately for 1 Month)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Related Unsolicited AEs During the Booster Phase up to Month 19
Percentage of ParticipantsBooster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
Percentage of Participants With Related Unsolicited AEs During the Booster Phase up to Month 195.1 (1.4 to 16.9)0.0 (0.0 to 16.8)
SecondaryPercentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Booster Vaccination

Solicited local AEs included pain, tenderness, induration (hardening), swelling and erythema (redness). Solicited systemic AEs included headache, myalgia (muscle pain), arthralgia (joint pain), fever (oral body temperature), flu-like symptoms, nausea, vomiting and fatigue. Two-sided 95% confidence intervals were calculated according to Altman method.

Time frame:
Within 7 days after booster vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Booster Vaccination
Percentage of ParticipantsBooster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
Solicited local AEs89.7 (76.4 to 95.9)42.1 (23.1 to 63.7)
Solicited systemic AEs51.3 (36.2 to 66.1)31.6 (15.4 to 54.0)
SecondaryPercentage of Participants With SAEs, AESIs, Solicited and Unsolicited AEs Stratified by Age Group During the Booster Phase

Percentage of participants with SAEs, AESIs, solicited and unsolicited AEs during booster phase stratified by age group 18-49 years and 50-65 years were reported. SAE: any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. AESI: any AEs of scientific/medical concern specific to study vaccine; Solicited AE: predefined reactions at injection site or systemic reactions after each vaccination. Unsolicited AE: any untoward medical occurrence in participant associated with use of study vaccine, whether or not related to study vaccine, reported in addition to solicited and any solicited symptom with onset outside specified period of follow-up.

Time frame:
SAEs and AESIs: From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months); AEs: From Day of vaccination in booster phase (Month 18) up to Month 19 (Approximately for 1 Month)
Reported as:
Number · Percentage of Participants
Percentage of Participants With SAEs, AESIs, Solicited and Unsolicited AEs Stratified by Age Group During the Booster Phase
Percentage of ParticipantsBooster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
SAE: 18-49 Years4.5 (0.8 to 21.8)0.0 (0.0 to 21.5)
SAE: 50-65 Years11.8 (3.3 to 34.3)0.0 (0.0 to 43.4)
AESI: 18-49 Years0.0 (0.0 to 14.9)0.0 (0.0 to 21.5)
AESI: 50-65 Years5.9 (1.0 to 27.0)0.0 (0.0 to 43.4)
Solicited AE: 18-49 Years86.4 (66.7 to 95.3)42.9 (21.4 to 67.4)
Solicited AE: 50-65 Years94.1 (73.0 to 99.0)80.0 (37.6 to 96.4)
Unsolicited AE: 18-49 Years9.1 (2.5 to 27.8)0.0 (0.0 to 21.5)
Unsolicited AE: 50-65 Years23.5 (9.6 to 47.3)20.0 (3.6 to 62.4)

Adverse events

Collected over Solicited AEs (systematic assessment [SA]): up to 7 days after each vaccination; Main study phase: unsolicited AEs (non-SA) including SAEs: up to Day 545; Booster phase: unsolicited AEs (non-SA): From day of vaccination in booster phase (Month 18) up to Month 19 (1 month), SAEs: From day of vaccination in booster phase (Month 18) up to Month 30 (12 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Study Phase: VLA15 With Alum Lower Dose0/97 (0%)4/97 (4.1%)94/97 (96.9%)
Main Study Phase: VLA15 With Alum Higher Dose0/98 (0%)4/98 (4.1%)97/98 (99%)
Main Study Phase: Placebo0/51 (0%)2/51 (3.9%)40/51 (78.4%)
Booster Phase: VLA15 With Alum Higher Dose0/39 (0%)3/39 (7.7%)35/39 (89.7%)
Booster Phase: Placebo0/19 (0%)0/19 (0%)11/19 (57.9%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventMain Study Phase: VLA15 With Alum Lower DoseMain Study Phase: VLA15 With Alum Higher DoseMain Study Phase: PlaceboBooster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
OsteoarthritisMusculoskeletal and connective tissue disorders0/971/980/511/390/19
SpondylolisthesisMusculoskeletal and connective tissue disorders0/970/980/511/390/19
Small intestinal obstructionGastrointestinal disorders0/970/980/511/390/19
Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/970/981/510/390/19
Prostate cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/970/981/510/390/19
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/970/980/510/390/19
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/970/980/510/390/19
VertigoEar and labyrinth disorders1/970/980/510/390/19
Obstructive pancreatitisGastrointestinal disorders1/970/980/510/390/19
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/971/980/510/390/19
Most frequent other events
Showing 10 of 23
Most frequent other events
EventMain Study Phase: VLA15 With Alum Lower DoseMain Study Phase: VLA15 With Alum Higher DoseMain Study Phase: PlaceboBooster Phase: VLA15 With Alum Higher DoseBooster Phase: Placebo
Injection site painGeneral disorders93/9795/9816/5135/395/19
MyalgiaMusculoskeletal and connective tissue disorders54/9755/9811/5111/391/19
HeadacheNervous system disorders45/9745/9818/518/394/19
Injection site erythemaGeneral disorders28/9741/988/517/393/19
FatigueGeneral disorders31/9733/9813/518/392/19
Injection site swellingGeneral disorders24/9732/981/513/391/19
Injection site indurationGeneral disorders27/9729/981/512/390/19
ArthralgiaMusculoskeletal and connective tissue disorders24/9723/988/514/391/19
Influenza like illnessGeneral disorders18/979/9810/511/390/19
NauseaGastrointestinal disorders18/9717/986/513/390/19

Baseline characteristics

Safety population included all participants who entered into the study and received at least 1 dose of vaccination.

Age, Continuous
Age, Continuous(years)VLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlaceboTotal
Main Study Phase43.5 ± 12.6143.0 ± 12.7645.0 ± 12.7943.6 ± 12.68
Booster Phase: VLA15 with Alum higher dose—46.5 ± 13.15—46.5 ± 13.15
Booster Phase: Placebo—38.8 ± 13.50—38.8 ± 13.50
Sex: Female, Male
Sex: Female, Male(Participants)VLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlaceboTotal
Main Study Phase — Female495034133
Main Study Phase — Male484817113
Booster Phase: VLA15 with Alum higher dose — Female023023
Booster Phase: VLA15 with Alum higher dose — Male016016
Booster Phase: Placebo — Female0707
Booster Phase: Placebo — Male012012
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VLA15 With Alum Lower DoseVLA15 With Alum Higher DosePlaceboTotal
Main Study Phase — American Indian or Alaska Native0000
Main Study Phase — Asian0101
Main Study Phase — Native Hawaiian or Other Pacific Islander0000
Main Study Phase — Black or African American4408
Main Study Phase — White919351235
Main Study Phase — More than one race0000
Main Study Phase — Unknown or Not Reported2002
Booster Phase: VLA15 with Alum higher dose — American Indian or Alaska Native0000
Booster Phase: VLA15 with Alum higher dose — Asian0101
Booster Phase: VLA15 with Alum higher dose — Native Hawaiian or Other Pacific Islander0000
Booster Phase: VLA15 with Alum higher dose — Black or African American0404
Booster Phase: VLA15 with Alum higher dose — White034034
Booster Phase: VLA15 with Alum higher dose — More than one race0000
Booster Phase: VLA15 with Alum higher dose — Unknown or Not Reported0000
Booster Phase: Placebo — American Indian or Alaska Native0000
Booster Phase: Placebo — Asian0000
Booster Phase: Placebo — Native Hawaiian or Other Pacific Islander0000
Booster Phase: Placebo — Black or African American0000
Booster Phase: Placebo — White019019
Booster Phase: Placebo — More than one race0000
Booster Phase: Placebo — Unknown or Not Reported0000
08

Study locations

5 sites
  • Clinical Research Consulting, LLC
    Milford, Connecticut 06460, United States
  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06905, United States
  • United Medical Associates
    Binghamton, New York 13901, United States
  • Regional Clinical Research, Inc
    Endwell, New York 13760, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Apr 2020, 9 months.

Results were first posted in Jul 2021, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2019
First posted
May 31, 2019
StartActual
Jul 1, 2019
Primary completionActual
Apr 7, 2020
CompletionActual
Mar 28, 2022
Results first posted
Jul 8, 2021
Last update
Apr 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03970733
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 31, 2019
Start date
Jul 1, 2019
Primary completion
Apr 7, 2020
Completion
Mar 28, 2022
Results posted
Jul 8, 2021
Last update
Apr 21, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VLA15

Start the discussion